Represent

Lobbying
Lobbying by Prime Therapeutics

Lobbying Relationship

Client

Prime Therapeutics

More records

Lobbying firm

Prime Therapeutics

More records

S.1339: "Pharmacy Benefit Manager Reform Act," provisions related to disclosure, audits and PBM contracting. Proposed amendments to S.1339 creating a default spread pricing option with options to elect pass-through payments for PBM compensation. S.3548: "Health Care Prices Revealed and Information to Consumers Explained Transparency Act," a bill to amend the Public Health Services Act to provide for hospital and insurer price transparency. H.R.5378: "Lower Costs, More Transparency Act," provisions related to PBM transparency and disclosure requirements. S.1542/H.R.6283: "The Delinking Revenue from Unfair Gouging (DRUG) Act," provisions dictating PBM contracting terms. S.127: Pharmacy Benefit Manager Transparency Act of 2023, a bill to prevent unfair and deceptive acts or practices and the dissemination of false information related to pharmacy benefit management services for prescription drugs, and for other purposes.
S.3430: "Better Mental Healthcare, Lower Cost Drugs & Extenders Act," provisions related to PBMs and pharmacy contracting. S.2973: "Modernizing and Ensuring PBM Accountability Act," provisions related to PBM contracting, audits and disclosures. H.R.5526: "Seniors Access to Critical Medications Act of 2023," provisions clarifying Medicare so that delivery of medicines through various methods or by allowing a family member or caregiver to pick up medication on behalf of a patient does not violate the Stark Law and does fall within the scope of Stark's IOAS exception. H.R.7512: "Real-Time Benefit Tool Implementation Act," legislation to ensure implementation of real-time benefit tools under part D of the Medicare program. Implementation of Center for Medicare and Medicaid Services Final Rule, Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs Final Rule, CMS-4192-F, CMS-1744-F, provisions related to changes in Pharmacy Direct and Indirect Renumeration. Implementation of H.R. 5376 (117th Congress)/P.L. 117-169 "The Inflation Reduction Act," provisions related to changes in Medicare Part D and government negotiation of drug prices. S.2305: "Biosimilars Red Tape Elimination Act," provisions relating improving the requirements for making a determination of interchangeability of a biological product and its reference product.

Duration: July 28, 2008 to October 16, 2015

General Issues: Health Issues, Medicare/Medicaid, Pharmacy, Alcohol & Drug Abuse, Law Enforcement/Crime/Criminal Justice, Insurance, Postal, Labor Issues/Antitrust/Workplace

Spending: about $6,892,019 (But it's complicated. Here's why.)

Agencies lobbied since 2008: U.S. Senate, House of Representatives, Health & Human Services - Dept of (HHS), Health & Human Services - Dept of (HHS), Substance Abuse & Mental Health Services Administration (SAMHSA), Federal Trade Commission (FTC), Office of Natl Drug Control Policy (NDCP), Centers For Medicare and Medicaid Services (CMS), Centers For Disease Control & Prevention (CDC), Office of Personnel Management (OPM), Food & Drug Administration (FDA), U.S. Senate,, White House Office

Bills mentioned

H.R.2430: FDA Reauthorization Act of 2017

Sponsor: Greg Walden (R-Ore.)

S.934: FDA Reauthorization Act of 2017

Sponsor: Lamar Alexander (R-Tenn.)

S.778: Prescription Drug Monitoring Act of 2017

Sponsor: Amy Klobuchar (D-Minn.)

S.771: Improving Access To Affordable Prescription Drugs Act

Sponsor: Al Franken (D-Minn.)

H.R.1776: Improving Access To Affordable Prescription Drugs Act

Sponsor: Jan Schakowsky (D-Ill.)

H.R.1939: Ensuring Seniors Access to Local Pharmacies Act of 2017

Sponsor: Morgan Griffith (R-Va.)

S.1044: Ensuring Seniors Access to Local Pharmacies Act of 2017

Sponsor: Shelley Moore Capito (R-W.Va.)

H.R.1703: Medical Product Communications Act of 2017

Sponsor: Morgan Griffith (R-Va.)

H.R.3528: Every Prescription Conveyed Securely Act

Sponsor: Katherine Clark (D-Mass.)

H.R.3447: FACTS Act of 2017

Sponsor: Lynn Jenkins (R-Kan.)

H.R.749: Lower Drug Costs through Competition Act

Sponsor: Kurt Schrader (D-Ore.)

S.974: Creating and Restoring Equal Access to Equivalent Samples Act of 2018

Sponsor: Patrick J. Leahy (D-Vt.)

H.R.2212: CREATES Act of 2017

Sponsor: Tom Marino (R-Pa.)

H.R.1628: American Health Care Act of 2017

Sponsor: Diane Black (R-Tenn.)

H.R.1316: Prescription Drug Price Transparency Act

Sponsor: Doug Collins (R-Ga.)

H.R.2026: Pharmaceutical Information Exchange Act

Sponsor: Brett Guthrie (R-Ky.)

H.R.413: Early Pell Promise Act

Sponsor: Brenda Lawrence (D-Mich.)

H.R.1038: Improving Transparency and Accuracy in Medicare Part D Spending Act

Sponsor: Morgan Griffith (R-Va.)

S.637: Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017

Sponsor: Ron Wyden (D-Ore.)

S.469: Affordable and Safe Prescription Drug Importation Act

Sponsor: Bernard Sanders (ID-Vt.)

H.R.1245: Affordable and Safe Prescription Drug Importation Act

Sponsor: Elijah E. Cummings (D-Md.)

S.1003: A bill to amend title XIX of the Social Security Act to add standards...

Sponsor: Charles E. Grassley (R-Iowa)

H.R.2051: FAST Generics Act of 2017

Sponsor: David McKinley (R-W.Va.)

H.R.1121: Pre-existing Conditions Protection Act of 2017

Sponsor: Greg Walden (R-Ore.)

S.191: Patient Freedom Act of 2017

Sponsor: Bill Cassidy (R-La.)

S.413: Improving Transparency and Accuracy in Medicare Part D Spending Act

Sponsor: Shelley Moore Capito (R-W.Va.)

H.R.4784: Lower Drug Costs through Competition Act

Sponsor: Kurt Schrader (D-Ore.)

S.2680: Mental Health Reform Act of 2016

Sponsor: Lamar Alexander (R-Tenn.)

S.2615: Increasing Competition in Pharmaceuticals Act

Sponsor: Susan Collins (R-Maine)

H.R.6: 21st Century Cures Act

Sponsor: Fred Upton (R-Mich.)

H.R.1600: Patients' Access to Treatments Act of 2015

Sponsor: David McKinley (R-W.Va.)

H.R.2841: FAST Generics Act of 2015

Sponsor: Steve Stivers (R-Ohio)

S.3056: CREATES Act of 2016

Sponsor: Patrick J. Leahy (D-Vt.)

H.R.6043: Fair Accountability and Innovative Research Drug Pricing Act of 2016

Sponsor: Jan Schakowsky (D-Ill.)

S.3335: Fair Accountability and Innovative Research Drug Pricing Act of 2016

Sponsor: Tammy Baldwin (D-Wis.)

S.2256: Co-Prescribing Saves Lives Act of 2016

Sponsor: Tim Kaine (D-Va.)

H.R.244: MAC Transparency Act

Sponsor: Doug Collins (R-Ga.)

H.R.793: Ensuring Seniors Access to Local Pharmacies Act of 2015

Sponsor: Morgan Griffith (R-Va.)

S.1190: Ensuring Seniors Access to Local Pharmacies Act of 2015

Sponsor: Shelley Moore Capito (R-W.Va.)

H.R.5951: Improving Transparency and Accuracy in Medicare Part D Spending Act

Sponsor: Morgan Griffith (R-Va.)

S.3308: Improving Transparency and Accuracy in Medicare Part D Spending Act

Sponsor: Shelley Moore Capito (R-W.Va.)

S.524: Comprehensive Addiction and Recovery Act of 2016

Sponsor: Sheldon Whitehouse (D-R.I.)

S.480: National All Schedules Prescription Electronic Reporting Reauthorization...

Sponsor: Jeanne Shaheen (D-N.H.)

H.R.1725: National All Schedules Prescription Electronic Reporting Reauthorization...

Sponsor: Edward Whitfield (R-Ky.)

H.R.4981: Opioid Use Disorder Treatment Expansion and Modernization Act

Sponsor: Larry Bucshon (R-Ind.)

H.R.4599: Reducing Unused Medications Act of 2016

Sponsor: Katherine Clark (D-Mass.)

S.2578: Reducing Unused Medications Act of 2016

Sponsor: Elizabeth Warren (D-Mass.)

H.R.3680: Co-Prescribing to Reduce Overdoses Act of 2016

Sponsor: John Sarbanes (D-Md.)

S.1945: Mental Health Reform Act of 2015

Sponsor: Bill Cassidy (R-La.)

S.2700: FDA and NIH Workforce Authorities Modernization Act

Sponsor: Lamar Alexander (R-Tenn.)

H.R.4577: Ensuring Seniors Access to Local Pharmacies Act of 2014

Sponsor: Morgan Griffith (R-Va.)

H.R.460: Patients' Access to Treatments Act of 2013

Sponsor: David McKinley (R-W.Va.)

H.R.4437: Generic Drug Pricing Fairness Act

Sponsor: Doug Collins (R-Ga.)

H.R.3392: Medicare Part D Patient Safety and Drug Abuse Prevention Act of 2013

Sponsor: Gus Bilirakis (R-Fla.)

S.867: Medicare Prescription Drug Program Integrity and Transparency Act of 2013

Sponsor: Mark Pryor (D-Ark.)

H.R.1188: Preserving Our Hometown Independent Pharmacies Act of 2013

Sponsor: Tom Marino (R-Pa.)

H.R.672: Prescription Drug Abuse Prevention and Treatment Act of 2013

Sponsor: Nick J. Rahall II (D-W.Va.)

S.348: Prescription Drug Abuse Prevention and Treatment Act of 2013

Sponsor: John D. Rockefeller IV (D-W.Va.)

S.1365: Part D Beneficiary Appeals Fairness Act

Sponsor: Bill Nelson (D-Fla.)

S.117: Medicare Prescription Drug Price Negotiation Act of 2013

Sponsor: Amy Klobuchar (D-Minn.)

H.R.1971: Pharmacy Competition and Consumer Choice Act of 2011

Sponsor: Cathy McMorris Rodgers (R-Wash.)

S.1058: Pharmacy Competition and Consumer Choice Act of 2011

Sponsor: Mark Pryor (D-Ark.)

H.R.4215: Medicare Pharmacy Transparency and Fair Auditing Act

Sponsor: Cathy McMorris Rodgers (R-Wash.)

S.1789: 21st Century Postal Service Act of 2012

Sponsor: Joseph I. Lieberman (I-Conn.)

H.R.2039: To suspend temporarily the duty on nightlights of plastic.

Sponsor: Steve Israel (D-N.Y.)

H.R.2309: Postal Reform Act of 2012

Sponsor: Darrell Issa (R-Calif.)

H.R.1946: Preserving Our Hometown Independent Pharmacies Act of 2011

Sponsor: Tom Marino (R-Pa.)

H.R.605: Patients' Freedom to Choose Act

Sponsor: Erik Paulsen (R-Minn.)

S.312: Patients' Freedom to Choose Act

Sponsor: Kay Bailey Hutchison (R-Texas)

H.R.4199: Patient Health and Real Medication Access Cost Savings Act of 2009

Sponsor: G. K. Butterfield (D-N.C.)

H.R.5234: PBM Audit Reform and Transparency Act of 2010

Sponsor: Anthony Weiner (D-N.Y.)

H.R.4489: FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act

Sponsor: Stephen F. Lynch (D-Mass.)

H.R.1204: Community Pharmacy Fairness Act of 2009

Sponsor: Anthony Weiner (D-N.Y.)

S.1697: Household Product Labeling Act of 2009

Sponsor: Al Franken (D-Minn.)

S.1796: America's Healthy Future Act of 2009

Sponsor: Max Baucus (D-Mont.)

H.R.3200: America's Affordable Health Choices Act of 2009

Sponsor: John D. Dingell (D-Mich.)

S.726: Promoting Innovation and Access to Life-Saving Medicine Act

Sponsor: Charles E. Schumer (D-N.Y.)

H.R.1549: Preservation of Antibiotics for Medical Treatment Act of 2009

Sponsor: Louise M. Slaughter (D-N.Y.)

H.R.1427: Promoting Innovation and Access to Life-Saving Medicine Act

Sponsor: Henry A. Waxman (D-Calif.)

H.R.1548: Pathway for Biosimilars Act

Sponsor: Anna G. Eshoo (D-Calif.)

H.R.1: American Recovery and Reinvestment Act of 2009

Sponsor: David R. Obey (D-Wis.)

S.1: American Recovery and Reinvestment Act of 2009

Sponsor: Harry Reid (D-Nev.)

H.R.5629: Pathway for Biosimilars Act

Sponsor: Anna G. Eshoo (D-Calif.)

H.R.1038: Access to Life-Saving Medicine Act

Sponsor: Henry A. Waxman (D-Calif.)

S.1695: Biologics Price Competition and Innovation Act of 2007

Sponsor: Edward M. Kennedy (D-Mass.)

S.1693: Wired for Health Care Quality Act

Sponsor: Edward M. Kennedy (D-Mass.)

H.R.6357: PRO(TECH)T Act of 2008

Sponsor: John D. Dingell (D-Mich.)

H.R.6898: Health-e Information Technology Act of 2008

Sponsor: Pete Stark (D-Calif.)

H.R.5442: TRUST in Health Information Act of 2008

Sponsor: Edward J. Markey (D-Mass.)

S.1814: Health Information Privacy and Security Act

Sponsor: Patrick J. Leahy (D-Vt.)

H.R.971: Community Pharmacy Fairness Act of 2007

Sponsor: Anthony Weiner (D-N.Y.)

H.R.6331: Medicare Improvements for Patients and Providers Act of 2008

Sponsor: Charles B. Rangel (D-N.Y.)

H.R.4169: Protecting Seniors Access to Proper Care Act of 2017

Sponsor: Kenny Marchant (R-Texas)

S.2460: Every Prescription Conveyed Securely Act

Sponsor: Michael Bennet (D-Colo.)

S.2554: Patient Right to Know Drug Prices Act

Sponsor: Susan Collins (R-Maine)

H.R.5343: Prescription Transparency Act of 2018

Sponsor: Buddy Carter (R-Ga.)

S.2553: Know the Lowest Price Act of 2018

Sponsor: Debbie Stabenow (D-Mich.)

H.R.6: SUPPORT for Patients and Communities Act

Sponsor: Greg Walden (R-Ore.)

H.R.5958: Phair Pricing Act of 2018

Sponsor: Doug Collins (R-Ga.)

H.R.6144: Know the Lowest Price Act of 2018

Sponsor: Lloyd Doggett (D-Texas)

H.R.5675: To amend title XVIII of the Social Security Act to require prescription...

Sponsor: Gus Bilirakis (R-Fla.)

H.R.6641: COST Act

Sponsor: Erik Paulsen (R-Minn.)

H.R.803: Improving Transparency and Accuracy in Medicare Part D Spending Act

Sponsor: Peter Welch (D-Vt.)

H.R.789: Improving Transparency and Accuracy in Medicare Part D Spending Act

Sponsor: Peter Welch (D-Vt.)

H.R.1035: Prescription Drug Price Transparency Act

Sponsor: Doug Collins (R-Ga.)

H.R.1034: Phair Pricing Act of 2019

Sponsor: Doug Collins (R-Ga.)

S.640: Phair Pricing Act of 2019

Sponsor: John Kennedy (R-La.)

H.R.965: CREATES Act of 2019

Sponsor: David Cicilline (D-R.I.)

S.340: CREATES Act of 2019

Sponsor: Patrick J. Leahy (D-Vt.)

S.64: Preserve Access to Affordable Generics and Biosimilars Act

Sponsor: Amy Klobuchar (D-Minn.)

S.476: Creating Transparency to Have Drug Rebates Unlocked (C–THRU) Act of 2019

Sponsor: Ron Wyden (D-Ore.)

S.657: A bill to amend title XXVII of the Public Health Service Act to...

Sponsor: Mike Braun (R-Ind.)

H.R.1264: Payment Commission Data Act of 2019

Sponsor: Lloyd Doggett (D-Texas)

H.R.1781: Payment Commission Data Act of 2019

Sponsor: Buddy Carter (R-Ga.)

S.801: A bill to amend titles XVIII and XIX of the Social Security Act to...

Sponsor: Catherine Cortez Masto (D-Nev.)

S.771: Small Business Cyber Training Act of 2019

Sponsor: Marco Rubio (R-Fla.)

H.R.1776: Captive Primate Safety Act

Sponsor: Earl Blumenauer (D-Ore.)

H.R.1316: Federal Labor-Management Partnership Act of 2019

Sponsor: Elijah E. Cummings (D-Md.)

S.1497: Health Care Price Check Act of 2019

Sponsor: Ron Wyden (D-Ore.)

S.1895: Lower Health Care Costs Act

Sponsor: Lamar Alexander (R-Tenn.)

S.1416: Affordable Prescriptions for Patients Act of 2019

Sponsor: John Cornyn (R-Texas)

S.1384: Prescription Drug Rebate Reform Act of 2019

Sponsor: Mitt Romney (R-Utah)

S.1532: Pharmacy Benefit Manager Accountability Study Act of 2019

Sponsor: Marsha Blackburn (R-Tenn.)

H.R.2115: Public Disclosure of Drug Discounts and Real-Time Beneficiary Drug Cost Act

Sponsor: Abigail Spanberger (D-Va.)

H.R.2087: Drug Price Transparency Act

Sponsor: Lloyd Doggett (D-Texas)

H.R.2376: Prescription Pricing for the People Act of 2019

Sponsor: Doug Collins (R-Ga.)

S.1227: Prescription Pricing for the People Act of 2019

Sponsor: Charles E. Grassley (R-Iowa)

S.1505: Medicare Prescription Drug Fraud Prevention Act of 2019

Sponsor: John Cornyn (R-Texas)

S.2199: Insulin Price Reduction Act

Sponsor: Jeanne Shaheen (D-N.H.)

H.R.3: Elijah E. Cummings Lower Drug Costs Now Act

Sponsor: Frank Pallone (D-N.J.)

S.2543: Prescription Drug Pricing Reduction Act of 2019

Sponsor: Charles E. Grassley (R-Iowa)

S.2247: Phair Relief Act of 2019

Sponsor: John Kennedy (R-La.)

H.R.2113: Prescription Drug STAR Act

Sponsor: Richard E. Neal (D-Mass.)

S.2119: Stop Improper Federal Bonuses Act

Sponsor: Deb Fischer (R-Neb.)

H.R.19: Lower Costs, More Cures Act of 2019

Sponsor: Greg Walden (R-Ore.)

S.3129: Lower Costs, More Cures Act of 2019

Sponsor: Michael D. Crapo (R-Idaho)

H.R.5304: PBM Transparency in Prescription Drug Costs Act

Sponsor: Kurt Schrader (D-Ore.)

S.3013: Encouraging Innovative Benefit Design to Lower Costs for Seniors Act

Sponsor: Patrick J. Toomey (R-Pa.)

H.R.1791: Children of Fallen Servicemembers AMT Relief Act of 2019

Sponsor: Rick Larsen (D-Wash.)

H.R.6739: Ensuring Seniors' Access to COVID Treatments Act

Sponsor: Sean Casten (D-Ill.)

H.R.6800: The Heroes Act

Sponsor: Nita M. Lowey (D-N.Y.)

H.R.5382: To create a mechanism whereby insulin manufacturers may sell directly to...

Sponsor: Jeff Fortenberry (R-Neb.)

S.4469: COVID–19 Treatment Coverage Act

Sponsor: Tina Smith (D-Minn.)

H.R.133: Consolidated Appropriations Act, 2021

Sponsor: Henry Cuellar (D-Texas)

S.2003: Suicide Prevention by Eliminating Excessive Digits Act of 2019

Sponsor: Joe Manchin III (D-W.Va.)

S.1895: A bill to require the Secretary of Health and Human Services to award...

Sponsor: Ben Ray Luján (D-N.M.)

H.R.19: Lower Costs, More Cures Act of 2021

Sponsor: Cathy McMorris Rodgers (R-Wash.)

H.R.3: Elijah E. Cummings Lower Drug Costs Now Act

Sponsor: Frank Pallone (D-N.J.)

S.464: Safe Step Act

Sponsor: Lisa Murkowski (R-Alaska)

H.R.2163: Safe Step Act

Sponsor: Raul Ruiz (D-Calif.)

S.164: Advancing Education on Biosimilars Act of 2021

Sponsor: Margaret Hassan (D-N.H.)

S.117: Intercountry Adoption Advisory Committee Act

Sponsor: Amy Klobuchar (D-Minn.)

S.415: A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to...

Sponsor: Bill Cassidy (R-La.)

S.2003: Central American Women and Children Protection Act of 2021

Sponsor: Marco Rubio (R-Fla.)

S.2164: Lower Costs, More Cures Act of 2021

Sponsor: Michael D. Crapo (R-Idaho)

H.R.2759: Pharmacy and Medically Underserved Areas Enhancement Act

Sponsor: G. K. Butterfield (D-N.C.)

H.R.3831: Seniors Securing Access to Vital and Essential Prescription Drugs Act

Sponsor: Susie Lee (D-Nev.)

S.1773: Prescription Drug Pricing Dashboard Act

Sponsor: Bob Casey (D-Pa.)

H.R.2846: Ensuring Access to Lower-Cost Medicines for Seniors Act of 2021

Sponsor: David McKinley (R-W.Va.)

H.R.5304: Extending Government Funding and Delivering Emergency Assistance Act

Sponsor: Rosa DeLauro (D-Conn.)

S.CON.RES.14: A concurrent resolution setting forth the congressional budget for the...

Sponsor: Bernard Sanders (ID-Vt.)

H.R.5237: Reduced Costs and Continued Cures Act of 2021

Sponsor: Scott Peters (D-Calif.)

S.2327: Seniors Prescription Drug Relief Act

Sponsor: Bill Cassidy (R-La.)

H.R.3684: Infrastructure Investment and Jobs Act

Sponsor: Peter A. DeFazio (D-Ore.)

H.R.5376: Inflation Reduction Act of 2022

Sponsor: John Yarmuth (D-Ky.)

S.3700: Affordable Insulin Now Act

Sponsor: Raphael Warnock (D-Ga.)

H.R.6833: Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023

Sponsor: Angie Craig (D-Minn.)

H.R.2069: Home Loan Quality Transparency Act of 2021

Sponsor: Nydia M. Velázquez (D-N.Y.)

S.4293: Pharmacy Benefit Manager Transparency Act of 2022

Sponsor: Maria Cantwell (D-Wash.)

S.1388: Prescription Pricing for the People Act of 2021

Sponsor: Charles E. Grassley (R-Iowa)

H.R.4390: PROTECT 340B Act of 2021

Sponsor: David McKinley (R-W.Va.)

H.R.7666: Restoring Hope for Mental Health and Well-Being Act of 2022

Sponsor: Frank Pallone (D-N.J.)

H.R.8487: Improving Seniors’ Timely Access to Care Act of 2022

Sponsor: Suzan K. DelBene (D-Wash.)

H.R.2617: Consolidated Appropriations Act, 2023

Sponsor: Gerald E. Connolly (D-Va.)

S.127: Pharmacy Benefit Manager Transparency Act of 2023

Sponsor: Maria Cantwell (D-Wash.)

H.R.1352: Increasing Access to Biosimilars Act of 2023

Sponsor: Richard Hudson (R-N.C.)

S.113: Prescription Pricing for the People Act of 2023

Sponsor: Charles E. Grassley (R-Iowa)

H.R.4011: TACT Act of 2023

Sponsor: Gus Bilirakis (R-Fla.)

S.1339: Pharmacy Benefit Manager Reform Act

Sponsor: Bernard Sanders (ID-Vt.)

H.R.3862: Spent Fuel Prioritization Act of 2023

Sponsor: Mike Levin (D-Calif.)

H.R.3561: PATIENT Act of 2023

Sponsor: Cathy McMorris Rodgers (R-Wash.)

H.R.3281: Transparent PRICE Act

Sponsor: Cathy McMorris Rodgers (R-Wash.)

H.R.2681: Small Business Taxpayer Bill of Rights Act of 2023

Sponsor: David Kustoff (R-Tenn.)

H.R.2679: Pharmacy Benefits Manager Accountability Act

Sponsor: Ann McLane Kuster (D-N.H.)

S.1967: PBM Act

Sponsor: Robert Menendez (D-N.J.)

S.2052: Protect Patient Access to Pharmacies Act

Sponsor: Jon Tester (D-Mont.)

S.954: Affordable Insulin Now Act of 2023

Sponsor: Raphael Warnock (D-Ga.)

S.1269: INSULIN Act of 2023

Sponsor: Jeanne Shaheen (D-N.H.)

H.R.5378: Lower Costs, More Transparency Act

Sponsor: Cathy McMorris Rodgers (R-Wash.)

S.2305: Biosimilar Red Tape Elimination Act

Sponsor: Mike Lee (R-Utah)

H.R.4507: Transparency in Coverage Act of 2023

Sponsor: Robert Good (R-Va.)

H.R.4527: Health DATA Act of 2023

Sponsor: Lori Chavez-DeRemer (R-Ore.)

H.R.5372: Expanding Seniors' Access to Lower Cost Medicines Act of 2023

Sponsor: John Joyce (R-Pa.)

H.R.5385: Medicare PBM Accountability Act

Sponsor: Greg Landsman (D-Ohio)

H.R.5386: Cutting Copays Act

Sponsor: Morgan McGarvey (D-Ky.)

H.R.3284: Providers and Payers COMPETE Act

Sponsor: Michael C. Burgess (R-Texas)

S.2973: Modernizing and Ensuring PBM Accountability Act

Sponsor: Ron Wyden (D-Ore.)

H.R.3682: Cady Housh and Gemesha Thomas Student Suicide Prevention Act of 2023

Sponsor: Emanuel Cleaver II (D-Mo.)

S.3548: Health Care Prices Revealed and Information to Consumers Explained...

Sponsor: Mike Braun (R-Ind.)

S.1542: DRUG Act

Sponsor: Roger Marshall (R-Kan.)

H.R.6283: DRUG Act

Sponsor: Mariannette Miller-Meeks (R-Iowa)

S.3430: Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023

Sponsor: Ron Wyden (D-Ore.)

H.R.5461: Ensuring Access to Lower-Cost Medicines for Seniors Act of 2023

Sponsor: Ann McLane Kuster (D-N.H.)

S.2436: NO PBMs Act

Sponsor: Joe Manchin III (D-W.Va.)

H.R.2880: Protecting Patients Against PBM Abuses Act

Sponsor: Buddy Carter (R-Ga.)

H.R.4881: To amend title XVIII of the Social Security Act to limit cost sharing...

Sponsor: Nicole Malliotakis (R-N.Y.)

H.R.5393: To amend title XVIII of the Social Security Act to ensure fair...

Sponsor: Morgan Griffith (R-Va.)

H.R.5376: Share the Savings with Seniors Act

Sponsor: Mariannette Miller-Meeks (R-Iowa)

H.R.5526: Seniors’ Access to Critical Medications Act of 2023

Sponsor: Diana Harshbarger (R-Tenn.)

H.R.7512: Real-Time Benefit Tool Implementation Act

Sponsor: Jodey Arrington (R-Texas)

Show All Mentioned Bills

Lobbyists

Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.

Lobbyist	Covered positions?
Stacey Fahrner	VP Government Affairs
Jerome Steffl	n/a
Julie Cantor-Weinberg	n/a
Jerome L. Steffl	n/a
Jerome Steffl Mr.	n/a

Disclosures Filed

Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.

1st Quarter, 2024

Q1 Report

In Q1, Prime Therapeutics had in-house lobbyists. The report was filed on April 22. Original Filing: 301572418.xml

Lobbying Issues

S.1339: "Pharmacy Benefit Manager Reform Act," provisions related to disclosure, audits and PBM contracting. Proposed amendments to S.1339 creating a default spread pricing option with options to elect pass-through payments for PBM compensation. S.3548: "Health Care Prices Revealed and Information to Consumers Explained Transparency Act," a bill to amend the Public Health Services Act to provide for hospital and insurer price transparency. H.R.5378: "Lower Costs, More Transparency Act," provisions related to PBM transparency and disclosure requirements. S.1542/H.R.6283: "The Delinking Revenue from Unfair Gouging (DRUG) Act," provisions dictating PBM contracting terms. S.127: Pharmacy Benefit Manager Transparency Act of 2023, a bill to prevent unfair and deceptive acts or practices and the dissemination of false information related to pharmacy benefit management services for prescription drugs, and for other purposes.

Agencies Lobbied

Type of Issue

Lobbying Issues

S.3430: "Better Mental Healthcare, Lower Cost Drugs & Extenders Act," provisions related to PBMs and pharmacy contracting. S.2973: "Modernizing and Ensuring PBM Accountability Act," provisions related to PBM contracting, audits and disclosures. H.R.5526: "Seniors Access to Critical Medications Act of 2023," provisions clarifying Medicare so that delivery of medicines through various methods or by allowing a family member or caregiver to pick up medication on behalf of a patient does not violate the Stark Law and does fall within the scope of Stark's IOAS exception. H.R.7512: "Real-Time Benefit Tool Implementation Act," legislation to ensure implementation of real-time benefit tools under part D of the Medicare program. Implementation of Center for Medicare and Medicaid Services Final Rule, Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs Final Rule, CMS-4192-F, CMS-1744-F, provisions related to changes in Pharmacy Direct and Indirect Renumeration. Implementation of H.R. 5376 (117th Congress)/P.L. 117-169 "The Inflation Reduction Act," provisions related to changes in Medicare Part D and government negotiation of drug prices. S.2305: "Biosimilars Red Tape Elimination Act," provisions relating improving the requirements for making a determination of interchangeability of a biological product and its reference product.

Agencies Lobbied

Type of Issue

4th Quarter, 2023

Q4 Report

In Q4, Prime Therapeutics had in-house lobbyists. The report was filed on Jan. 18. Original Filing: 301528700.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

S. 3430, Better Mental Healthcare, Lower Cost Drugs & Extenders Act-provisions related to PBMs and pharmacy contracting. S. 2973 Modernizing and Ensuring PBM Accountability Act -provisions related to PBM contracting, audits and disclosures. Implementation of Center for Medicare and Medicaid Services Final Rule, Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs Final Rule, CMS-4192-F, CMS-1744-F, provisions related to changes in Pharmacy Direct and Indirect Renumeration. H.R. 5461 Ensuring Access to Lower Cost Medicines for Seniors Act of 2023-provisions related to cost-sharing for generics and biosimilars in Medicare Part D. S. 2436 Neighborhood Options for Patients Buying Medicines (NO PBMs) Act-provisions related to pharmacy contracting under Medicare. H.R. 2880 Protecting Patients Against PBM Abuses Act-provisions regulating PBM reimbursement in Part D contracts. H.R. 5386 Cutting Copays Act provisions relating to changes to co-pays for Medicare Part D low-income beneficiaries. H.R. 4881 To amend title XVIII of the Social Security Act to limit cost sharing for drugs under the Medicare program. H.R. 5372 Expanding Seniors Access to Lower Cost Medicines Act of 2023-to amend Title XVIII of the Social Security Act to facilitate midyear formulary changes for biosimilars. H.R. 5393 The Transparency and Fairness for Pharmacists Act-provisions relating to pharmacy assessment in Medicare Part D. H.R. 5385 Medicare PBM Accountability Act; to amend Title XVIII of the Social Security Act to establish pharmacy benefit manager reporting requirements with respect to prescription drug plans and MA-PD plans under Medicare Part D. H.R. 1352, Increasing Access to Biosimilars Act of 2023-provisions related to a demonstration project providing additional provider payments for providers of biosimilars. Implementation of H.R. 5376 (117th Congress)/P.L. 117-169 The Inflation Reduction Act-provisions related to changes in Medicare Part D and government negotiation of drug prices.

Agencies Lobbied

Type of Issue

3rd Quarter, 2023

Q3 Report

In Q3, Prime Therapeutics had in-house lobbyists. The report was filed on Oct. 20, 2023. Original Filing: 301512773.xml

Lobbying Issues

S. 954: Affordable Insulin Now Act of 2023, provisions related to cost-sharing for insulin. S. 1269: INSULIN Act of 2023, provisions related to cost-sharing for insulin. H.R. 5378: The Lower Costs, More Transparency Act, provisions related to PBM transparency. S. 2305: Biosimilar Red Tape Elimination Act, provisions related to addressing biosimilar interchangeability. H.R. 4507: Transparency in Coverage Act of 2023, provisions related to PBM transparency. H.R. 4527: Health DATA Act provisions related to plan fiduciaries access to data. H.R. 5378: The Lower Costs, More Transparency Act, Sections 105, 106, 109, 110, 202, 401, 402 and 403, provisions related to PBM transparency and disclosure. S. 127: PBM Transparency Act of 2023, provisions related to PBM disclosure and contracting arrangements. S. 1339: PBM Reform Act, provisions related to PBM disclosure and contracting arrangements.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2023

Q2 Report

In Q2, Prime Therapeutics had in-house lobbyists. The report was filed on July 18, 2023. Original Filing: 301480151.xml

Lobbying Issues

PBM Transparency-Issues concerning PBM reporting of rebates and payments through the pharmaceutical supply chain. S. 127, The Pharmacy Benefit Manager Transparency Act of 2023," provisions related to the Federal Trade Commission regulation of PBMs. H.R. 4011, Timely Access to Clinical Treatment (TACT) Act of 2023, provisions on pharmacy access standards. Issues related to cost-sharing for insulin and other therapies in the commercial market. S. 1339, the Pharmacy Benefit Manager Reform Act provisions related to PBM disclosure, fee pass through and fee structures. H.R. 3862, Improving Transparency to Lower Drug Cost Act of 2021 (117th Congress)-provisions related to PBM transparency and disclosure. H.R. 3561, The PATIENT Act, provisions related to disclosure of drug price concessions and highly-rebated drugs. H.R. 37999, the CHOICE Act, potential amendments related to PBM pharmacy contracting practices. Issues related to patient cost-sharing and drug coupons. H.R. 3281/H.R. 2681, The Transparence PRICE Act, issues related to disclosure of drug price concessions. H.R. 2679, Pharmacy Benefit Manager Accountability Act, provisions related to client disclosure of drug price concessions particularly coupon use.

Agencies Lobbied

Type of Issue

Lobbying Issues

Implementation of the Inflation Reduction Act of 2022, P.L. 169- Provisions on Medicare Part D modernization and drug price negotiation. Implementation of Center for Medicare and Medicaid Services Final Rule, Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs Final Rule, CMS-4192-F, CMS-1744-F, provisions related to changes in Pharmacy Direct and Indirect Renumeration. S. 1967, Patients Before Middlemen Act, provisions governing how PBM compensation and use of metrics in determining drug rebates. S. 2052, A bill to amend title XVIII of the Social Security Act to enforce any willing pharmacy requirements and establish safeguards to ensure patient access to pharmacists in Medicare Part D and for other purposes. S. 2543 (116th Congress, Prescription Drug Pricing Reform Act of 2019 provisions on drug pricing disclosures. Issues related to utilization of real-time benefit checks.

Agencies Lobbied

Type of Issue

1st Quarter, 2023

Q1 Report

In Q1, Prime Therapeutics had in-house lobbyists. The report was filed on April 20, 2023. Original Filing: 301466725.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Implementation of the Inflation Reduction Act of 2022, P.L. 117-169 provisions on Medicare Part D modernization and drug price negotiation. Implementation of Center for Medicare and Medicaid Services Final Rule, Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs Final Rule, CMS-4192-F, CMS-1744-F, provisions related to changes in Pharmacy Direct and Indirect Renumeration. CMS proposed rule (CMS-4201-P) Medicare Program; Contract Year 2024 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly provisions related to the definition of Gross Covered Prescription Drug Costs.

Agencies Lobbied

Type of Issue

4th Quarter, 2022

Q4 Report

In Q4, Prime Therapeutics had in-house lobbyists. The report was filed on Jan. 19, 2023. Original Filing: 301435080.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2022

Q3 Report

In Q3, Prime Therapeutics had in-house lobbyists. The report was filed on Oct. 19, 2022. Original Filing: 301409834.xml

Lobbying Issues

Education on the value of biosimilars; H.R. 19/S. 2164: "Lower Cost, More Cures Act," provisions on drug prices and Part D cost-sharing and Part D reform. H.R. 5376/P.L. 117-169: "Build Back Better Act"/"Inflation Reduction Act," provisions relating to insulin cost-sharing; repeal of the rebate rule. S. 3700/H.R. 6833: "Affordable Insulin Now Act," provisions related to cost-sharing for insulin in Medicare and private plans. Draft versions of the "INSULIN Act," provisions on cost-sharing, utilization management and rebates for insulin. S. 4293: "The Pharmacy Benefit Manager Transparency Act of 2022," provisions on the FTC regulation of PBMs. S. 1388: "Prescription Pricing for the People Act of 2021," provisions related to an FTC study of PBMs; provisions related to restrictions on spread pricing in the commercial market for PBMs. H.R. 7666: "The Restoring Hope for Mental Health and Well-Being Act of 2022," Title VI, Sec. 602, Oversight of Pharmacy Benefit Manager Services.

Agencies Lobbied

Type of Issue

Lobbying Issues

Final Rule, Department of Health and Human Services: Office of Inspector General, issued November 20, 2020 entitled "Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Services Fees." Outreach on pharmacy direct and indirect remuneration in Medicare Part D and CMS-4192-P, Proposed and Final Rules, Medicare Program: Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Program. H.R. 19/S. 2164: "Lower Cost, More Cures Act," provisions on drug prices and Part D cost-sharing and Part D reform. H.R. 5376/P.L. 117-169: "Inflation Reduction Act"/"Build Back Better Act," provisions relating to insulin cost-sharing; Medicaid and Medicare drug pricing; Medicare Part D reform, repeal of the rebate rule. S. 3700/H.R. 6833: "Affordable Insulin Now Act," provisions related to cost-sharing for insulin in Medicare and private plans and mental health issues as they relate to prescription drug plans. Draft versions of the "INSULIN Act," provisions on cost-sharing, utilization management and rebates for insulin. H.R. 8487: "Seniors Timely Access to Care Act," general education on prior authorization.

Agencies Lobbied

Type of Issue

2nd Quarter, 2022

Q2 Report

In Q2, Prime Therapeutics had in-house lobbyists. The report was filed on July 19, 2022. Original Filing: 301386809.xml

Lobbying Issues

Education on the value of biosimilars; HR 19/S 2164-Lower Cost, More Cures Act, provisions on drug prices and Part D cost-sharing and Part D reform; HR 3-Elijah E. Cummings Lower Drug Costs Act Now, provisions establishing drug pricing and Part D cost sharing; value-based contracting for pharmaceuticals; H.R. 5376, Build Back Better Act, provisions relating to insulin cost-sharing; repeal of the rebate rule and audit/transparency provisions on PBMs; S. 3700/H.R. 6833, Affordable Insulin Now Act, provisions related to cost-sharing for insulin in Medicare and private plans and 116th Congress H.R. 2069; draft versions of the INSULIN Act, provisions on cost-sharing, utilization management and rebates for insulin; S. 4293 The Pharmacy Benefit Manager Transparency Act of 2022, provisions on the FTC regulation of PBMs and S. 1388, Prescription Pricing for the People Act of 2021, provisions related to an FTC study of PBMs; provisions related to restrictions on spread pricing in the commercial market for PBMs, and HR. 4390, Protect 430(b) Act of 2021, provisions related to the treatment of 340(b) drug discount program by PBMs.

Agencies Lobbied

Type of Issue

Lobbying Issues

Final Rule, Department of Health and Human Services: Office of Inspector General, issued November 20, 2020 entitled Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Services Fees; outreach on pharmacy direct and indirect remuneration in Medicare Part D and CMS-4192-P, Proposed and Final Rules, Medicare Program: Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Program;" HR 19/S 2164-Lower Cost, More Cures Act, provisions on drug prices and Part D cost-sharing and Part D reform; HR 3-Elijah E. Cummings Lower Drug Costs Act Now, provisions establishing drug pricing and Part D cost sharing; value-based contracting for pharmaceuticals; H.R. 5376, Build Back Better Act, provisions relating to insulin cost-sharing; Medicaid and Medicare drug pricing; Medicare Part D reform, repeal of the rebate rule and audit/transparency provisions on PBMs; S. 3700/H.R. 6833, Affordable Insulin Now Act, provisions related to cost-sharing for insulin in Medicare and private plans and mental health issues as they relate to prescription drug plans; draft versions of the INSULIN Act, provisions on cost-sharing, utilization management and rebates for insulin.

Agencies Lobbied

Type of Issue

1st Quarter, 2022

Q1 Report

In Q1, Prime Therapeutics had in-house lobbyists. The report was filed on April 19, 2022. Original Filing: 301363006.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Implementation of S2003 of the SUPPORT Act of Patients and Communities Act, provisions related to the implementation of Every Prescription Conveyed Securely Act; Final Rule, Department of Health and Human Services: Office of Inspector General, issued November 20, 2020 entitled Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Services Fees; outreach on pharmacy direct and indirect remuneration in Medicare Part D and CMS-4192-P, Proposed Rule, Medicare Program: Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Program; HR19 / S2164-Lower Cost, More Cures Act, provisions on drug prices and Part D cost-sharing and Part D reform; HR3-Elijah E. Cummings Lower Drug Costs Act Now,-provisions establishing drug pricing and Part D cost sharing; value-based contracting for pharmaceuticals; HR 5376, Build Back Better Act, provisions relating to insulin cost-sharing; Medicaid and Medicare drug pricing; Medicare Part D reform, repeal of the rebate rule and audit/transparency provisions on PBMs; S3700 / HR6833, Affordable Insulin Now Act, provisions related to cost-sharing for insulin in Medicare and private plans and mental health issues as they relate to prescription drug plans.

Agencies Lobbied

Type of Issue

4th Quarter, 2021

Q4 Report

In Q4, Prime Therapeutics had in-house lobbyists. The report was filed on Jan. 19, 2022. Original Filing: 301328759.xml

Lobbying Issues

Education on the value of biosimilars; outreach on PBMs role in social determinants of health and education and outreach on drug patent thickets and other pharmaceutical anticompetitive behavior and on the important role PBMs play in holding down drug costs; Final Rule, Department of Health and Human Services: Office of Inspector General, issued November 20, 2020 entitled Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Services Fees; outreach on pharmacy direct and indirect remuneration in Medicare Part D; HR 19/S 2164 - Lower Cost, More Cures Act, provisions on drug prices and Part D cost-sharing and Part D reform; HR 3 - Elijah E. Cummings Lower Drug Costs Act Now, provisions establishing drug pricing and Part D cost sharing; value-based contracting for pharmaceuticals; 116th Congress S. 4199, H.R. 3684/ P.L. 117-58, Infrastructure Investment Act, provisions related to the repeal of a rule repealing the safeharbor for drug rebate; H.R. 5376, Build Back Better Act, provisions relating to insulin cost-sharing; repeal of the rebate rule and audit/transparency provisions on PBMs.

Agencies Lobbied

Type of Issue

Lobbying Issues

Implementation of S. 2003 of the SUPPORT Act of Patients and Communities Act, provisions related to the implementation of Every Prescription Conveyed Securely Act; Final Rule, Department of Health and Human Services: Office of Inspector General, issued November 20, 2020 entitled Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Services Fees; outreach on pharmacy direct and indirect remuneration in Medicare Part D; HR 19/S 2164 - Lower Cost, More Cures Act, provisions on drug prices and Part D cost-sharing and Part D reform; HR 3 - Elijah E. Cummings Lower Drug Costs Act Now, provisions establishing drug pricing and Part D cost sharing; value-based contracting for pharmaceuticals; 116th Congress S. 4199, H.R. 3684/ P.L. 117-58, Infrastructure Investment Act, provisions related to the repeal of a rule repealing the safeharbor for drug rebate; H.R. 5376, Build Back Better Act, provisions relating to insulin cost-sharing; Medicaid and Medicare drug pricing; Medicare Part D reform, repeal of the rebate rule and audit/transparency provisions on PBMs.

Agencies Lobbied

Type of Issue

3rd Quarter, 2021

Q3 Report

In Q3, Prime Therapeutics had in-house lobbyists. The report was filed on Oct. 18, 2021. Original Filing: 301301773.xml

Lobbying Issues

116th Congress S. 1895, The Lower Health Care Costs Act, Sec. 306 Health Plan Oversight of PBMs; 116th Congress H.R. 19-Lower Cost, More Cures Act, provisions on drug prices and Part D cost-sharing; 116th Congress H.R. 3-Elijah E. Cummings Lower Drug Costs Act Now,--provisions establishing drug pricing and Part D cost sharing; Value-based contracting for pharmaceuticals; 116th Congress H.R. 5304, PBM Transparency in Prescription Drug Costs Act,--provisions related to PBM contracting; education on the value of biosimilars; outreach on PBMs role in social determinants of health and education and outreach on drug patent thickets and other pharmaceutical anticompetitive behavior; S.Con.Res.14 - A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031 provisions related to drug pricing and a change to the safe harbor rules for drug rebates.

Agencies Lobbied

Type of Issue

Lobbying Issues

Implementation of S. 2003 of the SUPPORT Act of Patients and Communities Act,--provisions related to the implementation of Every Prescription Conveyed Securely Act, Final Rule, Department of Health and Human Services: Office of Inspector General, issued November 20, 2020 entitled Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Services Fees,; outreach on pharmacy direct and indirect remuneration in Medicare Part D; H.R. 19/S. 2164-Lower Cost, More Cures Act, provisions on drug prices and Part D cost-sharing and Part D reform; H.R. 3-Elijah E. Cummings Lower Drug Costs Act Now, --Provisions establishing drug pricing and Part D cost sharing; value-based contracting for pharmaceuticals; 116th Congress S. 4199, Prescription Drug Pricing Reduction Act of 2020,--provisions related to PBMs, Part D cost-sharing, inflation rebates and drug pricing; H.R. 2846, Ensuring Access to Lower-Cost Medicines for Seniors Act of 2021-formulary tiering of biosimilars and generics in Medicare Part D; . H.R.5237 -"To amend titles XI, XVIII, and XIX of the Social Security Act to lower prescription drug prices in the Medicare and Medicaid programs, to improve transparency related to pharmaceutical prices and transactions, to lower patients' out-of-pocket costs, and to ensure accountability to taxpayers, and for other purposes--provisions related to drug price negotiation, PBM audits, pharmacy disclosures and payments and drug rebates; S. 2327, Seniors Prescription Drug Relief Act, provisions allowing Medicare beneficiaries to spread their cost-sharing across a plan year; H.R. 3684, Infrastructure Investment Act,--provisions related to the repeal of a rule repealing the safe harbor for drug rebate; S.Con.Res.14 - A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031 provisions related to drug pricing and a change to the safe harbor rules for drug rebates.

Agencies Lobbied

Type of Issue

2nd Quarter, 2021

Q2 Report

In Q2, Prime Therapeutics had in-house lobbyists. The report was filed on July 20, 2021. Original Filing: 301284675.xml

Lobbying Issues

116th Congress S. 1895, The Lower Health Care Costs Act, Sec. 306 Health Plan Oversight of PBMs ; 116th Congress HR 19-Lower Cost, More Cures Act, provisions on drug prices and Part D cost-sharing; 116th Congress HR 3-Elijah E. Cummings Lower Drug Costs Act Now, --Provisions establishing drug pricing and Part D cost sharing; S. 464/H.R. 2163, Safe Step Act,-Amending ERISA to specify exceptions for medication step therapy; Value-based contracting for pharmaceuticals; 116th Congress H.R. 5304, PBM Transparency in Prescription Drug Costs Act,-provisions related to PBM contracting; S. 164/P.S. 117-8 Advancing Education on Biosimilars Act of 2021-provisions related to an FDA campaign for prescriber education on biosimilars; S. 415/P.L. 117-9, A bill to clarify the meaning of a new chemical entity by the FDA; ; potential suspension of pharmacy audits during the public health emergency and reform of the orphan drug act; measures to combat pharma patent thickets

Agencies Lobbied

Type of Issue

Lobbying Issues

Implementation of S. 2003 of the SUPPORT Act of Patients and Communities Act, provisions related to the implementation of Every Prescription Conveyed Securely Act,; Final Rule, Department of Health and Human Services: Office of Inspector General, issued November 20, 2020 entitled Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Services Fees,; outreach on pharmacy direct and indirect remuneration in Medicare Part D; HR 19/S 2164-Lower Cost, More Cures Act, provisions on drug prices and Part D cost-sharing and Part D reform; HR 3-Elijah E. Cummings Lower Drug Costs Act Now, --Provisions establishing drug pricing and Part D cost sharing; value-based contracting for pharmaceuticals; 116th Congress S. 4199, Prescription Drug Pricing Reduction Act of 2020,-provisions related to PBMs, Part D cost-sharing, inflation rebates and drug pricing; H.R. 2759, Pharmacy and Medically Underserved Areas Enhancement Act, To amend title XVIII of the Social Security Act to provide for coverage under the Medicare program of pharmacists services; H.R. 3831, To amend title XVII of the Social Security Act to provide for certain rules regarding the treatment of eligible retirement plans in determining the eligibility of individuals for premium and cost-sharing subsidies in Medicare Part D; S. 1773, Prescription Drug Pricing Dashboard Act,-provisions related to a CMS dashboards on prescription drug spending; H.R. 2846, Ensuring Access to Lower-Cost Medicines for Seniors Act of 2021-formulary tiering of biosimilars and generics in Medicare Part D; potential suspension of pharmacy audits during the public health emergency; and Part D reform and modernization

Agencies Lobbied

Type of Issue

1st Quarter, 2021

Q1 Report

In Q1, Prime Therapeutics had in-house lobbyists. The report was filed on April 19, 2021. Original Filing: 301258506.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Implementation of S.2003 of the SUPPORT Act of Patients and Communities Act, provisions related to the implementation of Every Prescription Conveyed Securely Act. Final Rule, Department of Health and Human Services: Office of Inspector General, issued November 20, 2020 entitled Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Services Fees, outreach on pharmacy direct and indirect remuneration in Medicare Part D. 116th Congress HR 19, Lower Cost, More Cures Act, provisions on drug prices and Part D cost-sharing. 116th Congress HR 3, Elijah E. Cummings Lower Drug Costs Act Now, provisions establishing drug pricing and Part D cost sharing; value-based contracting for pharmaceuticals.

Agencies Lobbied

Type of Issue

4th Quarter, 2020

Q4 Report

In Q4, Prime Therapeutics had in-house lobbyists. The report was filed on Jan. 20, 2021. Original Filing: 301241138.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Implementation of S. 2003 of the SUPPORT Act of Patients and Communities Act, provisions related to the implementation of Every Prescription Conveyed Securely Act. Presidential Executive Order on lowering Prices for Patients by Eliminating Kickbacks to Middlemen, issued July 24, 2020 requiring the completion of rulemaking to exclude from safe harbor protection drug rebates in Medicare Part D; and, Final Rule, Department of Health and Human Services: Office of Inspector General, issued November 20, 2020 entitled Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Services Fees. Presidential Executive Order on Lowering Drug Prices by Putting America First, Issued Sept 13, 2020 creating a Most Favored Nation Price for drugs in Medicare Part D. Outreach on pharmacy direct and indirect remuneration in Medicare Part D. H.R.19: Lower Cost, More Cures Act, provisions on drug prices and Part D cost-sharing. H.R.3: Elijah E. Cummings Lower Drug Costs Act Now, provisions establishing drug pricing and Part D cost sharing.

Agencies Lobbied

Type of Issue

3rd Quarter, 2020

Q3 Report

In Q3, Prime Therapeutics had in-house lobbyists. The report was filed on Oct. 20, 2020. Original Filing: 301218556.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R. 6800: HEROES Act, Sec. 30205 Requiring Coverage Under Medicare PDPs and MA-PD Plans Without the Imposition of Cost Sharing or Utilization Management Requirements of Drugs Intended to Treat COVID-During Certain Emergencies. S. 4469: COVID-19 Treatment Coverage Act Sec. 6 Coverage of COVID-19 Drugs at no cost sharing under Medicare prescription drug plans. Value-based contracting and Medicaid Best Price. Implementation of Sec. 20003 the SUPPORT Act for Patients and Communities Act, provisions related to the implementation of Every Prescription Conveyed Securely Act. S. 3013: Encouraging Innovative Benefit Design to Lower Costs for Seniors Act, to amend Title XVIII of the Social Security Act to allow for the offering of additional prescription drug plans under Medicare Part D. Presidential Executive Order on Lowering Prices for Patients by Eliminating Kickbacks to Middlemen, issued July 24, 2020 requiring the completion of rulemaking to exclude from safe harbor protection drug rebates in Medicare Part D. Presidential Executive Order on Lowering Drug Prices by Putting America First, issued September 13, 2020 creating a Most Favored Nation Price for drugs in Medicare Part B and Part D. Outreach on pharmacy direct and indirect remuneration in Medicare Part D and on real time benefit tools.

Agencies Lobbied

Type of Issue

2nd Quarter, 2020

Q2 Report

In Q2, Prime Therapeutics had in-house lobbyists. The report was filed on July 20, 2020. Original Filing: 301200963.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

HR 3: Elijah E. Cummings Lower Drugs Cost Now Act,-provisions to modernize the Part D benefit and provisions that require HHS to negotiate prices for certain drugs. HR 19/S 3129: The Lower Costs, More Cures Act, reforms drug pricing by promoting greater competition and redesign of the Medicare Part D benefit. HR 6739: Ensuring Seniors Access to COVID Treatments Act. HR 6800: HEROES Act, Sec. 30205 Requiring Coverage Under Medicare PDPS and MA-PD Plans, Without the Imposition of Cost Sharing or Utilization Management Requirements, of Drugs Intended to Treat Covid - During Certain Emergencies. Value-based contracting and Medicaid Best Price. Sec. 3714 of P.L. 116-136 The CARES Act, related to requiring that Medicare Part D and C plan beneficiaries have access to 90-day prescriptions at the beneficiarys request. S. 2543: The Prescription Drug Pricing Reduction Act (PDPRA) of 2019 -provisions on Medicare Part D and PBMs. Outreach on pharmacy direct and indirect remuneration in Medicare Part D and real time benefit tools. Implementation of Sec. 2003 SUPPORT for Patients and Communities Act, provisions related to implementation of Every Prescription Conveyed Securely Act.

Agencies Lobbied

Type of Issue

1st Quarter, 2020

Q1 Report

In Q1, Prime Therapeutics had in-house lobbyists. The report was filed on April 20, 2020. Original Filing: 301177144.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R.3: Elijah E. Cummings Lower Drugs Cost Now Act, provisions to modernize the Part D benefit and provisions that require HHS to negotiate prices for certain drugs. H.R. 19/S. 3129: The Lower Costs, More Cures Act, Reforms drug pricing by promoting greater competition and redesign of the Medicare Part D benefit. H.R. 5304: legislation to amend title IIVII of the Public Health Service Act to require health plan oversight of pharmacy benefit managers. S. 3013: Encouraging Innovative Benefit Design to Lower Costs for Seniors Act, provisions allowing for the offering of additional prescription drug plans under Medicare Part. Draft legislation Patient Affordability, Value and Efficiency Act, provisions encouraging wider use of value-based contracting. Outreach and education on pharmacy Direct and Indirect Negotiation and a real-time benefit tool. Provisions of Sec. 3714 of P.L. 116-136: The CARES Act, related to requiring that Medicare Part D and C plan beneficiaries have access to 90-day prescriptions at the beneficiaries request. Implementation of P.L. 115-271, Sec. 2003, SUPPORT For Patients and Communities Act, provisions related to implementation of Every Prescription Conveyed Securely Act,

Agencies Lobbied

Type of Issue

4th Quarter, 2019

Q4 Report

In Q4, Prime Therapeutics had in-house lobbyists. The report was filed on Jan. 21, 2020. Original Filing: 301124947.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R. 965/S. 340: The Creating and Restoring Equal Access to Equivalent Samples (CREATES Act). Implementation of the e-prescribing provisions of the controlled substances provisions of the SUPPORT Act (P.L. 115-271). S. 1895: The Lower Health Care Costs Act, Sec. 306 Health Plan Oversight of PBMs. S. 2199: The Insulin Price Reduction Act, requires private health insurance plans and Medicare Part D plans to eliminate rebates for insulin and limit out of pocket costs. H.R. 3: Elijah E. Cummings Lower Drugs Costs Now Act, provisions to modernize the Part D benefit and provisions that require HHS to negotiate prices for certain drugs. H.R. 19/S. 3129: The Lower Costs, More Cures Act, reforms drug pricing by promoting greater competition and redesigns the Medicare Part D drug benefit. S. 3013: Encouraging Innovative Benefit Design to Lower Costs for Seniors Act, provisions allowing for the offering of additional prescription drug plans under Medicare Part D. S. 2543: The Prescription Drug Pricing Reduction Act, legislation to amend Medicare and Medicaid to lower prescription drug prices and strengthen safeguards related to prescription drug. Provisions related to inflation protection and PBM transparency. Medicare Advantage and Part D Drug Pricing Final Rule, (CMS-4180-F), provisions related to pharmacy Direct and Indirect Negotiation and a real-time benefit tool. Outreach and education on pharmacy DIR in Medicare Part D. H.R. 2115: Public Disclosure of Drug Discounts and Real-time Beneficiary Drugs Costs Act, provisions requiring HHS to publish information online about discounts under Medicare Advantage and Part D and requirements related to real-time benefits tool implementation. H.R. 1791: The Payment Commission Data Act of 2019, legislation that would require government commission to receive rebate and other data from PBMs/Part D plans.

Agencies Lobbied

Type of Issue

3rd Quarter, 2019

Amendment

Prime Therapeutics amended a lobbying report for in-house lobbying in Q32019 on Oct. 22, 2019 Original Filing: 301079708.xml

Lobbying Issues

HR 803: Improving Transparency and Accuracy in Medicare Part D Drug Spending Act, pharmacy payments & adjustments in Part D/ DIR. HR 789: To amend title XVIII of the Social Security Act to prohibit prescription drug plan sponsors and MA-PD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. HR 1035: The Prescription Drug Price Transparency Act, requires greater transparency and accountability from PBMs. HR 1034/S 640: The Phair Pricing Act, lowers the cost of prescription medication for patients in the Medicare Part D program. HR 965/S 340: "The Creating and Restoring Equal Access To Equivalent Samples (CREATES) Act." S 64: "Preserve Access to Affordable Generics and Biosimilars Act," bars pay-for-delay for generics and biosimilars. Proposals to address pay-for-delay, orphan drug abuse and patent evergreening. Implementation of the e-prescribing provisions of controlled substances provisions of the SUPPORT Act, (P.L. 115-271). The Payment Commission Data Act, H.R. 1264, H.R. 1781 and S. 801: provisions allowing MACPAC and MedPAC access to certain drug price concession and rebate information. S. 1895: The Lower Health Care Costs Act, Sec. 306 Health Plan Oversight of PBMs. Issues related to implementation of a real-time benefit tool. S. 1416: The Affordable Prescriptions for Patients Act of 2019, address product hopping and patent thickets by giving the FTC greater powers to investigate and bring legal actions. S. 1384: The Prescription Drug Rebate Reform Act, would require all patients coinsurance obligations be set as a percentage of net price, rather than list price, before or after a deductible is met. S. 1532: The Pharmacy Benefit Manager Accountability Study Act of 2019, (provisions requiring GAO to submit a report on PBMs). H.R. 2115: the "Public Disclosure of Drug Discounts Act, requires PBMs to disclose the aggregate amount of rebates, discounts, and price concessions that PBMs negotiate with drug manufacturers, and make this information publicly available to allow the public to compare the aggregate rebates, discounts, and price concessions that PBMs receive. H.R. 2113: "The Prescription Drug STAR (Sunshine, Transparency, Accountability and Reporting) Act," provisions related to disclosure of PBM-pharmaceutical company negotiated rebates. H.R. 2376/S. 1227: Prescription Pricing for the People Act of 2019," FTC study of PBMs. S.2199: The Insulin Price Reduction Act, require private health insurance plans and Medicare Part D plans to eliminate rebates for insulin and limit out of pocket costs ($250 for individuals, and $500 for families) if manufacturers reduce insulin list prices to prices during plan year 2006 and do not raise insulin prices above inflation. H.R. 3: Lower Drug Costs Now Act of 2019, Provisions to establish a fair price negotiation program, protect the Medicare program from excessive price increases, and establish an out-of-pocket maximum for Medicare part D enrollment.

Agencies Lobbied

Type of Issue

Lobbying Issues

S.771/H.R.1776: Improving Access to Affordable Prescription Drugs Act, issues related to ensuring a competitive marketplace for prescription drugs. H.R.1316: The Prescription Drug Price Transparency Act, issues related to ensuring the continuity of MAC pricing. Medicare Program; Contract Year 2019 Policy and Technical Changes to the Medicare Advantage, Medicare Cost Plan, Medicare Fee-for-Service, the Medicare Prescription Drug Benefit Programs, and the PACE Program Proposed Rule & Request for Information--Provisions on Part D. CMS Proposed and Final Policy Changes and Updates for Medicare Advantage and the Prescription Drug Benefit Program for Contract Year 2019 (CMS-4182-P as in proposed and final version CMS-4182-F, particularly issues related to pharmacy DIR and implementation of a real-time-benefit tool); provisions in a Request for Information related to rebates at the point-of-sale and pharmacist direct and indirect renumeration. Outreach and education on pharmacy Direction and Indirection Remuneration in Medicare. Provisions related to opening the Medicare doughnut hole in P.L. 115-123. HR 803: Improving Transparency and Accuracy in Medicare Part D Drug Spending Act, pharmacy payments & adjustments in Part D/ DIR. HR 789: To amend title XVIII of the Social Security Act to prohibit prescription drug plan sponsors and MA-PD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies." HR 1035: The Prescription Drug Price Transparency Act, requires greater transparency and accountability from PBMs. HR 1034/S 640: The Phair Pricing Act, lowers the cost of prescription medication for patients in the Medicare Part D program. HR 965/S 340: "The Creating and Restoring Equal Access To Equivalent Samples (CREATES) Act." Proposals to address pay-for-delay, orphan drug abuse and patent evergreening. Implementation of the e-prescribing provisions of controlled substances provisions of the SUPPORT Act, (P.L. 115-271). The Payment Commission Data Act, H.R. 1264, H.R. 1781 and S. 801: provisions allowing MACPAC and MedPAC access to certain drug price concession and rebate information. S. 64: Preserve Access to Affordable Generics and Biosimilars Act, bars pay-for-delay for generics and biosimilars. S. 1416: The Affordable Prescriptions for Patients Act of 2019, address product hopping and patent thickets by giving the FTC greater powers to investigate and bring legal actions. S. 1384: The Prescription Drug Rebate Reform Act, would require all patients coinsurance obligations be set as a percentage of net price, rather than list price, before or after a deductible is met. S. 1505: a bill to require prescription drug plans and MA-PD plans to report potential fraud, waste, and abuse to the Secretary of Health and Human Services under Medicare part D, and for other purposes. S. 1532: The Pharmacy Benefit Manager Accountability Study Act of 2019, (Provisions requiring GAO to submit a report on PBMs). Modernization and cost-sharing of the Part D drug benefit. H.R. 2115: the "Public Disclosure of Drug Discounts Act, requires PBMs to disclose the aggregate amount of rebates, discounts, and price concessions that PBMs negotiate with drug manufacturers, and make this information publicly available to allow the public to compare the aggregate rebates, discounts, and price concessions that PBMs receive. H.R. 2113: "The Prescription Drug STAR (Sunshine, Transparency, Accountability and Reporting) Act," provisions related to disclosure of PBM-pharmaceutical company negotiated rebates. H.R. 2376/S. 1227: Prescription Pricing for the People Act of 2019, FTC study of PBMs. S.2199: The Insulin Price Reduction Act, require private health insurance plans and Medicare Part D plans to eliminate rebates for insulin and limit out of pocket costs ($250 for individuals, and $500 for families) if manufacturers reduce insulin list prices to prices during plan year 2006 and do not raise insulin prices above inflation. S.2543: The Prescription Drug Pricing Reduction Act (PDPRA) of 2019, -Legislation to amend Medicare and Medicaid to lower prescription drug prices and strengthen safeguards related to prescription drugs. Provisions related to inflation protection provisions and PBM transparency. S.2247: Phair Relief Act, Provisions related to pharmacy DIR. H.R. 3: Lower Drug Costs Now Act of 2019, Provisions to establish a fair price negotiation program, protect the Medicare program from excessive price increases, and establish an out-of-pocket maximum for Medicare part D enrollment. CMS Proposed rule: "Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses," (CMS-4180-P)-provisions related to pharmacy Direct and Indirect Negotiation.

Agencies Lobbied

Type of Issue

3rd Quarter, 2019

Q3 Report

In Q3, Prime Therapeutics had in-house lobbyists. The report was filed on Oct. 17, 2019. Original Filing: 301068585.xml

Lobbying Issues

HR 803: Improving Transparency and Accuracy in Medicare Part D Drug Spending Act, pharmacy payments & adjustments in Part D/ DIR. HR 789: To amend title XVIII of the Social Security Act to prohibit prescription drug plan sponsors and MA-PD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. HR 1035: The Prescription Drug Price Transparency Act, requires greater transparency and accountability from PBMs. HR 1034/S 640: The Phair Pricing Act, lowers the cost of prescription medication for patients in the Medicare Part D program. HR 965/S 340: "The Creating and Restoring Equal Access To Equivalent Samples (CREATES) Act." S 64: "Preserve Access to Affordable Generics and Biosimilars Act," bars pay-for-delay for generics and biosimilars. Proposals to address pay-for-delay, orphan drug abuse and patent evergreening. Implementation of the e-prescribing provisions of controlled substances provisions of the SUPPORT Act, (P.L. 115-271). The Payment Commission Data Act, H.R. 1264, H.R. 1781 and S. 801: provisions allowing MACPAC and MedPAC access to certain drug price concession and rebate information. S. 1895: The Lower Health Care Costs Act, Sec. 306 Health Plan Oversight of PBMs. Issues related to implementation of a real-time benefit tool. S. 1416: The Affordable Prescriptions for Patients Act of 2019, address product hopping and patent thickets by giving the FTC greater powers to investigate and bring legal actions. S. 1384: The Prescription Drug Rebate Reform Act, would require all patients coinsurance obligations be set as a percentage of net price, rather than list price, before or after a deductible is met. S. 1532: The Pharmacy Benefit Manager Accountability Study Act of 2019, (provisions requiring GAO to submit a report on PBMs). H.R. 2115: the "Public Disclosure of Drug Discounts Act, requires PBMs to disclose the aggregate amount of rebates, discounts, and price concessions that PBMs negotiate with drug manufacturers, and make this information publicly available to allow the public to compare the aggregate rebates, discounts, and price concessions that PBMs receive. H.R. 2087: "The STAR (Sunshine, Transparency, Accountability and Reporting) Act," provisions related to disclosure of PBM-pharmaceutical company negotiated rebates. H.R. 2376/S. 1227: Prescription Pricing for the People Act of 2019," FTC study of PBMs. S.2199: The Insulin Price Reduction Act, require private health insurance plans and Medicare Part D plans to eliminate rebates for insulin and limit out of pocket costs ($250 for individuals, and $500 for families) if manufacturers reduce insulin list prices to prices during plan year 2006 and do not raise insulin prices above inflation. H.R. 3: Lower Drug Costs Now Act of 2019, Provisions to establish a fair price negotiation program, protect the Medicare program from excessive price increases, and establish an out-of-pocket maximum for Medicare part D enrollment.

Agencies Lobbied

Type of Issue

Lobbying Issues

S.771/H.R.1776: Improving Access to Affordable Prescription Drugs Act, issues related to ensuring a competitive marketplace for prescription drugs. H.R.1316: The Prescription Drug Price Transparency Act, issues related to ensuring the continuity of MAC pricing. Medicare Program; Contract Year 2019 Policy and Technical Changes to the Medicare Advantage, Medicare Cost Plan, Medicare Fee-for-Service, the Medicare Prescription Drug Benefit Programs, and the PACE Program Proposed Rule & Request for Information--Provisions on Part D. CMS Proposed and Final Policy Changes and Updates for Medicare Advantage and the Prescription Drug Benefit Program for Contract Year 2019 (CMS-4182-P as in proposed and final version CMS-4182-F, particularly issues related to pharmacy DIR and implementation of a real-time-benefit tool); provisions in a Request for Information related to rebates at the point-of-sale and pharmacist direct and indirect renumeration. Outreach and education on pharmacy Direction and Indirection Remuneration in Medicare. Provisions related to opening the Medicare doughnut hole in P.L. 115-123. HR 803: Improving Transparency and Accuracy in Medicare Part D Drug Spending Act, pharmacy payments & adjustments in Part D/ DIR. HR 789: To amend title XVIII of the Social Security Act to prohibit prescription drug plan sponsors and MA-PD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies." HR 1035: The Prescription Drug Price Transparency Act, requires greater transparency and accountability from PBMs. HR 1034/S 640: The Phair Pricing Act, lowers the cost of prescription medication for patients in the Medicare Part D program. HR 965/S 340: "The Creating and Restoring Equal Access To Equivalent Samples (CREATES) Act." Proposals to address pay-for-delay, orphan drug abuse and patent evergreening. Implementation of the e-prescribing provisions of controlled substances provisions of the SUPPORT Act, (P.L. 115-271). The Payment Commission Data Act, H.R. 1264, H.R. 1781 and S. 801: provisions allowing MACPAC and MedPAC access to certain drug price concession and rebate information. S. 64: Preserve Access to Affordable Generics and Biosimilars Act, bars pay-for-delay for generics and biosimilars. S. 1416: The Affordable Prescriptions for Patients Act of 2019, address product hopping and patent thickets by giving the FTC greater powers to investigate and bring legal actions. S. 1384: The Prescription Drug Rebate Reform Act, would require all patients coinsurance obligations be set as a percentage of net price, rather than list price, before or after a deductible is met. S. 1505: a bill to require prescription drug plans and MA-PD plans to report potential fraud, waste, and abuse to the Secretary of Health and Human Services under Medicare part D, and for other purposes. S. 1532: The Pharmacy Benefit Manager Accountability Study Act of 2019, (Provisions requiring GAO to submit a report on PBMs). Modernization and cost-sharing of the Part D drug benefit. H.R. 2115: the "Public Disclosure of Drug Discounts Act, requires PBMs to disclose the aggregate amount of rebates, discounts, and price concessions that PBMs negotiate with drug manufacturers, and make this information publicly available to allow the public to compare the aggregate rebates, discounts, and price concessions that PBMs receive. H.R. 2087: "The STAR (Sunshine, Transparency, Accountability and Reporting) Act," provisions related to disclosure of PBM-pharmaceutical company negotiated rebates. H.R. 2376/S. 1227: Prescription Pricing for the People Act of 2019, FTC study of PBMs. S.2199: The Insulin Price Reduction Act, require private health insurance plans and Medicare Part D plans to eliminate rebates for insulin and limit out of pocket costs ($250 for individuals, and $500 for families) if manufacturers reduce insulin list prices to prices during plan year 2006 and do not raise insulin prices above inflation. S.2543: The Prescription Drug Pricing Reduction Act (PDPRA) of 2019, -Legislation to amend Medicare and Medicaid to lower prescription drug prices and strengthen safeguards related to prescription drugs. Provisions related to inflation protection provisions and PBM transparency. S.2247: Phair Relief Act, Provisions related to pharmacy DIR. H.R. 3: Lower Drug Costs Now Act of 2019, Provisions to establish a fair price negotiation program, protect the Medicare program from excessive price increases, and establish an out-of-pocket maximum for Medicare part D enrollment. CMS Proposed rule: "Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses," (CMS-4180-P)-provisions related to pharmacy Direct and Indirect Negotiation.

Agencies Lobbied

Type of Issue

2nd Quarter, 2019

Q2 Report

In Q2, Prime Therapeutics had in-house lobbyists. The report was filed on July 17, 2019. Original Filing: 301047855.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Legislation to address abuses of the REMS program to allow generic drugs to come to market faster. Request for information: "HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs," provisions affecting market competition for prescription drugs and the drug supply chain. HR 803: Improving Transparency and Accuracy in Medicare Part D Drug Spending Act, pharmacy payments & adjustments in Part D/ DIR. HR 789: To amend title XVIII of the Social Security Act to prohibit prescription drug plan sponsors and MA-PD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. HR 1035: The Prescription Drug Price Transparency Act, requires greater transparency and accountability from PBMs. HR 1034/S 640: The Phair Pricing Act, lowers the cost of prescription medication for patients in the Medicare Part D program. HR 965/S 340: "The Creating and Restoring Equal Access To Equivalent Samples (CREATES) Act." S 64: "Preserve Access to Affordable Generics and Biosimilars Act," bars pay-for-delay for generics and biosimilars. S 476: The Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act. S 657: Drug Price Transparency Act, eliminates rebates in ERISA plans. Proposed Rule: Fraud and Abuse: Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees, HHSIG-2019-0001-0001. Proposals to address pay-for-delay, orphan drug abuse and patent evergreening. Implementation of the e-prescribing provisions of controlled substances provisions of the SUPPORT Act, (P.L. 115-271). The Payment Commission Data Act, H.R. 1264, H.R. 1781 and S. 801: provisions allowing MACPAC and MedPAC access to certain drug price concession and rebate information. S. 1497: Health Care Price Check Act of 2019, requires Medicare and insurance companies to make available an online tool and a toll-free # for beneficiaries to inquire about the cost, for that specific consumer, of any services, procedure or product including prescription drugs. S. 1895: The Lower Health Care Costs Act, Sec. 306 Health Plan Oversight of PBMs. Issues related to implementation of a real-time benefit tool. S. 1416: The Affordable Prescriptions for Patients Act of 2019, address product hopping and patent thickets by giving the FTC greater powers to investigate and bring legal actions. S. 1384: The Prescription Drug Rebate Reform Act, would require all patients coinsurance obligations be set as a percentage of net price, rather than list price, before or after a deductible is met. S. 1532: The Pharmacy Benefit Manager Accountability Study Act of 2019, (provisions requiring GAO to submit a report on PBMs). H.R. 2115: the "Public Disclosure of Drug Discounts Act, requires PBMs to disclose the aggregate amount of rebates, discounts, and price concessions that PBMs negotiate with drug manufacturers, and make this information publicly available to allow the public to compare the aggregate rebates, discounts, and price concessions that PBMs receive. H.R. 2087: "The STAR (Sunshine, Transparency, Accountability and Reporting) Act," provisions related to disclosure of PBM-pharmaceutical company negotiated rebates. H.R. 2376/S. 1227: Prescription Pricing for the People Act of 2019," FTC study of PBMs.

Agencies Lobbied

Type of Issue

Lobbying Issues

S.771/H.R.1776: Improving Access to Affordable Prescription Drugs Act, issues related to ensuring a competitive marketplace for prescription drugs. H.R.1316: The Prescription Drug Price Transparency Act, issues related to ensuring the continuity of MAC pricing. Medicare Program; Contract Year 2019 Policy and Technical Changes to the Medicare Advantage, Medicare Cost Plan, Medicare Fee-for-Service, the Medicare Prescription Drug Benefit Programs, and the PACE Program Proposed Rule & Request for Information--Provisions on Part D. Request for Information: HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs, provisions affecting market competition for prescription drugs and the drug supply chain. CMS Proposed and Final Policy Changes and Updates for Medicare Advantage and the Prescription Drug Benefit Program for Contract Year 2019 (CMS-4182-P as in proposed and final version CMS-4182-F, particularly issues related to pharmacy DIR and implementation of a real-time-benefit tool); provisions in a Request for Information related to rebates at the point-of-sale and pharmacist direct and indirect renumeration. Proposed HHS-OIG rule currently under OMB review entitled, Removal of Safe Harbor Protections for Rebates to Plans or PBMs Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection, RIN-936-AAO8. (See https://www.reginfo.gov/public/do/eoReviewSearch for questions). Outreach and education on pharmacy Direction and Indirection Remuneration in Medicare. Provisions related to opening the Medicare doughnut hole in P.L. 115-123. HR 803: Improving Transparency and Accuracy in Medicare Part D Drug Spending Act, pharmacy payments & adjustments in Part D/ DIR. HR 789: To amend title XVIII of the Social Security Act to prohibit prescription drug plan sponsors and MA-PD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies." HR 1035: The Prescription Drug Price Transparency Act, requires greater transparency and accountability from PBMs. HR 1034/S 640: The Phair Pricing Act, lowers the cost of prescription medication for patients in the Medicare Part D program. HR 965/S 340: "The Creating and Restoring Equal Access To Equivalent Samples (CREATES) Act." S 476: The Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act. S 657: Drug Price Transparency Act, eliminates rebates in ERISA plans. Proposed Rule: Fraud and Abuse: Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees, HHSIG-2019-0001-0001. Proposals to address pay-for-delay, orphan drug abuse and patent evergreening. Implementation of the e-prescribing provisions of controlled substances provisions of the SUPPORT Act, (P.L. 115-271). The Payment Commission Data Act, H.R. 1264, H.R. 1781 and S. 801: provisions allowing MACPAC and MedPAC access to certain drug price concession and rebate information. S. 1497: Health Care Price Check Act of 2019, requires Medicare and insurance companies to make available an online tool and a toll-free # for beneficiaries to inquire about the cost, for that specific consumer, of any services, procedure or product including prescription drugs. S. 64: Preserve Access to Affordable Generics and Biosimilars Act, bars pay-for-delay for generics and biosimilars. S. 1416: The Affordable Prescriptions for Patients Act of 2019, address product hopping and patent thickets by giving the FTC greater powers to investigate and bring legal actions. S. 1384: The Prescription Drug Rebate Reform Act, would require all patients coinsurance obligations be set as a percentage of net price, rather than list price, before or after a deductible is met. S. 1505: a bill to require prescription drug plans and MA-PD plans to report potential fraud, waste, and abuse to the Secretary of Health and Human Services under Medicare part D, and for other purposes. S. 1532: The Pharmacy Benefit Manager Accountability Study Act of 2019, (Provisions requiring GAO to submit a report on PBMs). Modernization and cost-sharing of the Part D drug benefit. H.R. 2115: the "Public Disclosure of Drug Discounts Act, requires PBMs to disclose the aggregate amount of rebates, discounts, and price concessions that PBMs negotiate with drug manufacturers, and make this information publicly available to allow the public to compare the aggregate rebates, discounts, and price concessions that PBMs receive. H.R. 2087: "The STAR (Sunshine, Transparency, Accountability and Reporting) Act," provisions related to disclosure of PBM-pharmaceutical company negotiated rebates. H.R. 2376/S. 1227: Prescription Pricing for the People Act of 2019, FTC study of PBMs.

Agencies Lobbied

Type of Issue

1st Quarter, 2019

Q1 Report

In Q1, Prime Therapeutics had in-house lobbyists. The report was filed on April 18, 2019. Original Filing: 301030072.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

S.771/H.R.1776: Improving Access to Affordable Prescription Drugs Act--issues related to ensuring a competitive marketplace for prescription drugs. H.R.1316: The Prescription Drug Price Transparency Act--issues related to ensuring the continuity of MAC pricing. Medicare Program; Contract Year 2019 Policy and Technical Changes to the Medicare Advantage, Medicare Cost Plan, Medicare Fee-for-Service, the Medicare Prescription Drug Benefit Programs, and the PACE Program Proposed Rule & Request for Information --Provisions on Part D. Request for Information: HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs, provisions affecting market competition for prescription drugs and the drug supply chain. CMS Proposed and Final Policy Changes and Updates for Medicare Advantage and the Prescription Drug Benefit Program for Contract Year 2019 (CMS-4182-P), provisions in a Request for Information related to rebates at the point-of-sale and pharmacist direct and indirect renumeration. Proposed HHS-OIG rule currently under OMB review entitled, Removal of Safe Harbor Protections for Rebates to Plans or PBMs Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection, RIN-936-AAO8. (See https://www.reginfo.gov/public/do/eoReviewSearch for questions). Outreach and education on pharmacy Direction and Indirection Remuneration in Medicare. Provisions related to opening the Medicare doughnut hole in P.L. 115-123. HR 803: Improving Transparency and Accuracy in Medicare Part D Drug Spending Act Pharmacy payments & adjustments in Part D/ DIR. HR 789: To amend title XVIII of the Social Security Act to prohibit prescription drug plan sponsors and MA-PD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. HR 1035: The Prescription Drug Price Transparency Act, requires greater transparency and accountability from PBMs. HR 1034/S 640: The Phair Pricing Act, lowers the cost of prescription medication for patients in the Medicare Part D program. HR 965/S 340: The Creating and Restoring Equal Access To Equivalent Samples (CREATES) Act. S 64: Preserve Access to Affordable Generics and Biosimilars Act - Prohibits brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products. S 476: The Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act. S 657: Drug Price Transparency Act - eliminates rebates in ERISA plans. Proposed Rule: Fraud and Abuse: Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees, HHSIG-2019-0001-0001. Proposals to address pay-for-delay, orphan drug abuse and patent evergreening. Implementation of the e-prescribing provisions of controlled substances provisions of the SUPPORT Act, (P.L. 115-271). The Payment Commission Data Act H.R. 1264 and H.R. 1781 and S. 801 - Provisions allowing MACPAC and MedPAC access to certain drug price concession and rebate information.

Agencies Lobbied

Type of Issue

4th Quarter, 2018

Q4 Report

In Q4, Prime Therapeutics had in-house lobbyists. The report was filed on Jan. 22, 2019. Original Filing: 301014182.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2018

Q3 Report

In Q3, Prime Therapeutics had in-house lobbyists. The report was filed on Oct. 18, 2018. Original Filing: 300988375.xml

Lobbying Issues

S.2460/H.R.3528: Every Prescription Conveyed Securely Act--provisions requiring electronic prescribing of controlled substances in Medicare Part D; provisions added through amendment to H.R. 6 that limit who can use analgesic prescribing guidelines(became HR 6, which is awaiting President's signature). S.2554: "Patient Right to Know Drug Prices Act,"--provisions to prohibit the use of gag clauses or require that beneficiaries be charged lower prices (now PL 115-263). H.R.5343: "Prescription Transparency Act of 2018,"-- provisions to prohibit the use of gag clauses or require that beneficiaries be charged lower prices. H.R.5958: The Phair Pricing Act of 2018, provisions related to the use of quality provisions and provisions to prohibit the use of gag clauses or require that beneficiaries be charged lower prices. H.R.6144: Know the Lowest Price Act -provisions to prohibit the use of gag clauses or require that beneficiaries be charged lower prices. Request for Information: HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs, provisions affecting market competition for prescription drugs and the drug supply chain. H.R.5675: To amend title XVIII of the Social Security Act to require prescription drug plan sponsors under the Medicare program to establish drug management programs for at-risk beneficiaries; provisions mandating a Medicare lock-in program for Medicare beneficiaries at risk for opioid abuse.

Agencies Lobbied

Type of Issue

Lobbying Issues

Legislation to address abuses of the REMS program to allow generic drugs to come to market faster. H.R.2212/S.974: CREATES Act--provisions related to removing barriers to generic competition. H.R.1316: The Prescription Drug Price Transparency Act--issues related to ensuring the continuity of MAC pricing. S.2460/H.R.3528: Every Prescription Conveyed Securely Act--provisions requiring electronic prescribing of controlled substances in Medicare Part D; provisions added through amendment to H.R. 6 that limit who can use analgesic prescribing guidelines (became HR 6; awaiting President's signature). S.2554: "Patient Right to Know Drug Prices Act,"--provisions to prohibit the use of gag clauses or require that beneficiaries be charged lower prices (now PL 115-263). H.R.5343: "Prescription Transparency Act of 2018,"-- provisions to prohibit the use of gag clauses or require that beneficiaries be charged lower prices. H.R.5958: The Phair Pricing Act of 2018, provisions related to the use of quality provisions and provisions to prohibit the use of gag clauses or require that beneficiaries be charged lower prices. H.R.6144: Know the Lowest Price Act -provisions to prohibit the use of gag clauses or require that beneficiaries be charged lower prices. Request for Information: HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs, provisions affecting market competition for prescription drugs and the drug supply chain. H.R.5675: To amend title XVIII of the Social Security Act to require prescription drug plan sponsors under the Medicare program to establish drug management programs for at-risk beneficiaries Provisions mandating a Medicare lock-in program for Medicare beneficiaries at risk for opioid abuse.

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R.413/H.R.1038: Improving Transparency and Accuracy in Medicare Part D Spending Act--provisions restricting payer quality payment programs in Medicare Part D. S.771/H.R.1776: Improving Access to Affordable Prescription Drugs Act--issues related to ensuring a competitive marketplace for prescription drugs. H.R.1316: The Prescription Drug Price Transparency Act--issues related to ensuring the continuity of MAC pricing. S.2460/H.R.3528: Every Prescription Conveyed Securely Act--provisions requiring electronic prescribing of controlled substances in Medicare Part D; provisions added through amendment to H.R. 6 that limit who can use analgesic prescribing guidelines (became HR 6, awaiting President's signature). Medicare Program; Contract Year 2019 Policy and Technical Changes to the Medicare Advantage, Medicare Cost Plan, Medicare Fee-for-Service, the Medicare Prescription Drug Benefit Programs, and the PACE Program Proposed Rule & Request for Information --Provisions on Part D. H.R.5343: "Prescription Transparency Act of 2018,"-- provisions to prohibit the use of gag clauses or require that beneficiaries be charged lower prices. S.2553: "Know the Lowest Price Act," --"-- provisions to prohibit the use of gag clauses or require that beneficiaries be charged lower prices (now PL 115-262). H.R.5958: The Phair Pricing Act of 2018, provisions related to the use of quality provisions and provisions to prohibit the use of gag clauses or require that beneficiaries be charged lower prices. H.R.6144: Know the Lowest Price Act -provisions to prohibit the use of gag clauses or require that beneficiaries be charged lower prices. Request for Information: HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs, provisions affecting market competition for prescription drugs and the drug supply chain. H.R.5675: To amend title XVIII of the Social Security Act to require prescription drug plan sponsors under the Medicare program to establish drug management programs for at-risk beneficiaries Provisions mandating a Medicare lock-in program for Medicare beneficiaries at risk for opioid abuse. CMS Proposed and Final Policy Changes and Updates for Medicare Advantage and the Prescription Drug Benefit Program for Contract Year 2019 (CMS-4182-P), provisions in a Request for Information related to rebates at the point-of-sale and pharmacist direct and indirect renumeration. H.R.6641: True Cost-sharing of Seniors Drugs Transparency Act provisions related to pharmacy gag clause. Proposed HHS-OIG rule currently under OMB review entitled, Removal of Safe Harbor Protections for Rebates to Plans or PBMs Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection, RIN-936-AAO8. (See https://www.reginfo.gov/public/do/eoReviewSearch for questions). Outreach and education on pharmacy Direction and Indirection Remuneration in Medicare.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2018

Q2 Report

In Q2, Prime Therapeutics had in-house lobbyists. The report was filed on July 18, 2018. Original Filing: 300967811.xml

Lobbying Issues

H.R.1939/S.1044: Ensuring Seniors Access to Local Pharmacies Act of 2017 (any willing pharmacy bill)--Provisions limiting payers' ability to selectively contract. S.2460/H.R.3528: Every Prescription Conveyed Securely Act--provisions requiring electronic prescribing of controlled substances in Medicare Part D; provisions added through amendment to H.R. 6 that limit who can use analgesic prescribing guidelines. S.2554: "Patient Right to Know Drug Prices Act,"--provisions to prohibit the use of gag clauses or require that beneficiaries be charged lower prices. H.R.5343: "Prescription Transparency Act of 2018,"-- provisions to prohibit the use of gag clauses or require that beneficiaries be charged lower prices. H.R.5958: The Phair Pricing Act of 2018, provisions related to the use of quality provisions and provisions to prohibit the use of gag clauses or require that beneficiaries be charged lower prices. H.R.6144: Know the Lowest Price Act -provisions to prohibit the use of gag clauses or require that beneficiaries be charged lower prices. Request for Information: HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs, provisions affecting market competition for prescription drugs and the drug supply chain. H.R.5675: To amend title XVIII of the Social Security Act to require prescription drug plan sponsors under the Medicare program to establish drug management programs for at-risk beneficiaries; provisions mandating a Medicare lock-in program for Medicare beneficiaries at risk for opioid abuse.

Agencies Lobbied

Type of Issue

Lobbying Issues

Legislation to address abuses of the REMS program to allow generic drugs to come to market faster. H.R.2212/S.974: CREATES Act--provisions related to removing barriers to generic competition. H.R.1939/S.1044: Ensuring Seniors Access to Local Pharmacies Act of 2017 (any willing pharmacy bill)--provisions limiting payers' ability to selectively contract. H.R.1316: The Prescription Drug Price Transparency Act--issues related to ensuring the continuity of MAC pricing. S.2460/H.R.3528: Every Prescription Conveyed Securely Act--provisions requiring electronic prescribing of controlled substances in Medicare Part D; provisions added through amendment to H.R. 6 that limit who can use analgesic prescribing guidelines. S.2554: "Patient Right to Know Drug Prices Act,"--provisions to prohibit the use of gag clauses or require that beneficiaries be charged lower prices. H.R.5343: "Prescription Transparency Act of 2018,"-- provisions to prohibit the use of gag clauses or require that beneficiaries be charged lower prices. H.R.5958: The Phair Pricing Act of 2018, provisions related to the use of quality provisions and provisions to prohibit the use of gag clauses or require that beneficiaries be charged lower prices. H.R.6144: Know the Lowest Price Act -provisions to prohibit the use of gag clauses or require that beneficiaries be charged lower prices. Request for Information: HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs, provisions affecting market competition for prescription drugs and the drug supply chain. H.R.5675: To amend title XVIII of the Social Security Act to require prescription drug plan sponsors under the Medicare program to establish drug management programs for at-risk beneficiaries Provisions mandating a Medicare lock-in program for Medicare beneficiaries at risk for opioid abuse.

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R.413/H.R.1038: Improving Transparency and Accuracy in Medicare Part D Spending Act--provisions restricting payer quality payment programs in Medicare Part D. S.771/H.R.1776: Improving Access to Affordable Prescription Drugs Act--issues related to ensuring a competitive marketplace for prescription drugs. H.R.1939/S.1044, Ensuring Seniors Access to Local Pharmacies Act of 2017 (any willing pharmacy bill)--provisions limiting payers' ability to selectively contract. H.R.1316: The Prescription Drug Price Transparency Act--issues related to ensuring the continuity of MAC pricing. S.2460/H.R.3528: Every Prescription Conveyed Securely Act--provisions requiring electronic prescribing of controlled substances in Medicare Part D; provisions added through amendment to H.R. 6 that limit who can use analgesic prescribing guidelines. Medicare Program; Contract Year 2019 Policy and Technical Changes to the Medicare Advantage, Medicare Cost Plan, Medicare Fee-for-Service, the Medicare Prescription Drug Benefit Programs, and the PACE Program Proposed Rule & Request for Information --Provisions on Part D. H.R.5343: "Prescription Transparency Act of 2018,"-- provisions to prohibit the use of gag clauses or require that beneficiaries be charged lower prices. S.2553: "Know the Lowest Price Act," --"-- provisions to prohibit the use of gag clauses or require that beneficiaries be charged lower prices. H.R.5958: The Phair Pricing Act of 2018, provisions related to the use of quality provisions and provisions to prohibit the use of gag clauses or require that beneficiaries be charged lower prices. H.R.6144: Know the Lowest Price Act -provisions to prohibit the use of gag clauses or require that beneficiaries be charged lower prices. Request for Information: HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs, provisions affecting market competition for prescription drugs and the drug supply chain. H.R.5675: To amend title XVIII of the Social Security Act to require prescription drug plan sponsors under the Medicare program to establish drug management programs for at-risk beneficiaries Provisions mandating a Medicare lock-in program for Medicare beneficiaries at risk for opioid abuse. CMS Proposed and Final Policy Changes and Updates for Medicare Advantage and the Prescription Drug Benefit Program for Contract Year 2019 (CMS-4182-P), provisions in a Request for Information related to rebates at the point-of-sale and pharmacist direct and indirect renumeration.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2018

Q1 Report

In Q1, Prime Therapeutics had in-house lobbyists. The report was filed on April 18, 2018. Original Filing: 300947433.xml

Lobbying Issues

S.778: Prescription Drug Monitoring Act--issues related to dispensers access to PDMP data across state lines. S.771/H.R.1776: Improving Access to Affordable Prescription Drugs Act--issues related to ensuring a competitive marketplace for prescription drugs. H.R.1939/S.1044: Ensuring Seniors Access to Local Pharmacies Act of 2017 (any willing pharmacy bill)--Provisions limiting payers' ability to selectively contract. S.2460/H.R.3528: Every Prescription Conveyed Securely Act--provisions requiring electronic prescribing of controlled substances in Medicare Part D (House Only). S.2554: "Patient Right to Know Drug Prices Act,"--provisions to prohibit the use of gag clauses or require that beneficiaries be charged lower prices. H.R.5343: "Prescription Transparency Act of 2018,"-- provisions to prohibit the use of gag clauses or require that beneficiaries be charged lower prices.

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R.749/S.974: "Lower Drugs Costs Through Competition Act,"--increasing generic competition. Legislation to address abuses of the REMS program to allow generic drugs to come to market faster. H.R.2212/S.974: CREATES Act--provisions related to removing barriers to generic competition. H.R.1939/S.1044: Ensuring Seniors Access to Local Pharmacies Act of 2017 (any willing pharmacy bill)--provisions limiting payers' ability to selectively contract. Use of prescription drug coupons in federal programs and the ACA exchanges and their effects on insurance premiums. H.R.1316: The Prescription Drug Price Transparency Act--issues related to ensuring the continuity of MAC pricing. S.771/H.R.1776: Improving Access to Affordable Prescription Drugs Act--issues related to ensuring a competitive marketplace for prescription drugs. S.778 Prescription Drug Monitoring Act--issues related to dispensers access to PDMP data across state lines. S.2460/H.R.3528: Every Prescription Conveyed Securely Act--provisions requiring electronic prescribing of controlled substances in Medicare Part D (House Only). S.2554: "Patient Right to Know Drug Prices Act,"--provisions to prohibit the use of gag clauses or require that beneficiaries be charged lower prices. H.R.5343: "Prescription Transparency Act of 2018,"-- provisions to prohibit the use of gag clauses or require that beneficiaries be charged lower prices.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2017

Q4 Report

In Q4, Prime Therapeutics had in-house lobbyists. The report was filed on Jan. 18, 2018. Original Filing: 300927382.xml

Lobbying Issues

S.778: Prescription Drug Monitoring Act--issues related to dispensers access to PDMP data across state lines. S.771/H.R.1776: Improving Access to Affordable Prescription Drugs Act--issues related to ensuring a competitive marketplace for prescription drugs. H.R.1939/S.1044: Ensuring Seniors Access to Local Pharmacies Act of 2017 (any willing pharmacy bill)--Provisions limiting payers' ability to selectively contract. Use of prescription drug coupons in federal programs and the ACA exchanges and their effects on insurance premiums. H.R. 3528: Every Prescription Conveyed Securely Act--provisions requiring electronic prescribing of controlled substances in Medicare Part D (House Only). H.R.3447: Furthering Access to Coordinated Treatment for Seniors Act of 2017--provisions to provide prescription drug plans with Medicare Parts A and B data. Draft legislation "to amend title XVIII of the Social Security Act to provide for electronic prior authorization under Medicare Part D for covered part D drugs and for other purposes" (House only).

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R.749/S.974: "Lower Drugs Costs Through Competition Act,"--increasing generic competition. Legislation to address abuses of the REMS program to allow generic drugs to come to market faster. H.R.2212/S.974: CREATES Act--provisions related to removing barriers to generic competition. H.R.1939/S.1044: Ensuring Seniors Access to Local Pharmacies Act of 2017 (any willing pharmacy bill)--provisions limiting payers' ability to selectively contract. Use of prescription drug coupons in federal programs and the ACA exchanges and their effects on insurance premiums. H.R.1628: The American Health Care Act of 2017 and The Better Care Reconciliation Act--provisions related to the stability of the exchanges. H.R.1316: The Prescription Drug Price Transparency Act--issues related to ensuring the continuity of MAC pricing. S.771/H.R.1776: Improving Access to Affordable Prescription Drugs Act--issues related to ensuring a competitive marketplace for prescription drugs. S.778 Prescription Drug Monitoring Act--issues related to dispensers access to PDMP data across state lines. H.R.2026: Pharmaceutical Information Exchange Act--provisions relating to payer access to pharma data. H.R.3528: Every Prescription Conveyed Securely Act--provisions requiring electronic prescribing of controlled substances in Medicare Part D (House Only). H.R.3447: Furthering Access to Coordinated Treatment for Seniors Act of 2017--provisions to provide prescription drug plans with Medicare Parts A and B data. Draft legislation "to amend title XVIII of the Social Security Act to provide for electronic prior authorization under Medicare Part D for covered part D drugs and for other purposes" (House only).

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2017

Q3 Report

In Q3, Prime Therapeutics had in-house lobbyists. The report was filed on Oct. 19, 2017. Original Filing: 300908559.xml

Lobbying Issues

H.R.2430/S.934: FDA Reauthorization Act of 2017--provisions to ensure greater market competition for generics & biosimilars. S.778: Prescription Drug Monitoring Act--issues related to dispensers access to PDMP data across state lines. S.771/H.R.1776: Improving Access to Affordable Prescription Drugs Act--issues related to ensuring a competitive marketplace for prescription drugs. H.R.1939/S.1044: Ensuring Seniors Access to Local Pharmacies Act of 2017 (any willing pharmacy bill)--Provisions limiting payers' ability to selectively contract. Use of prescription drug coupons in federal programs and the ACA exchanges and their effects on insurance premiums. H.R.1703: Medical Product Communications Act of 2017--provisions relating to greater market access for off-label indications. H.R. 3528: Every Prescription Conveyed Securely Act--provisions requiring electronic prescribing of controlled substances in Medicare Part D (House Only). H.R.3447: Furthering Access to Coordinated Treatment for Seniors Act of 2017--provisions to provide prescription drug plans with Medicare Parts A and B data. Draft legislation "to amend title XVIII of the Social Security Act to provide for electronic prior authorization under Medicare Part D for covered part D drugs and for other purposes" (House only).

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R.749/S.974: "Lower Drugs Costs Through Competition Act,"--increasing generic competition. Legislation to address abuses of the REMS program to allow generic drugs to come to market faster. H.R.2212/S.974: CREATES Act--provisions related to removing barriers to generic competition. H.R.2430/S.934: FDA Reauthorization Act of 2017--provisions to ensure greater market competition for generics & biosimilars. H.R.1939/S.1044: Ensuring Seniors Access to Local Pharmacies Act of 2017 (any willing pharmacy bill)--provisions limiting payers' ability to selectively contract. Use of prescription drug coupons in federal programs and the ACA exchanges and their effects on insurance premiums. H.R.1628: The American Health Care Act of 2017 and The Better Care Reconciliation Act--provisions related to the stability of the exchanges. H.R.1316: The Prescription Drug Price Transparency Act--issues related to ensuring the continuity of MAC pricing. S.771/H.R.1776: Improving Access to Affordable Prescription Drugs Act--issues related to ensuring a competitive marketplace for prescription drugs. H.R.1703: Medical Product Communications Act of 2017--provisions relating to greater market access for off-label indications. S.778 Prescription Drug Monitoring Act--issues related to dispensers access to PDMP data across state lines. H.R.2026: Pharmaceutical Information Exchange Act--provisions relating to payer access to pharma data. H.R.3528: Every Prescription Conveyed Securely Act--provisions requiring electronic prescribing of controlled substances in Medicare Part D (House Only). H.R.3447: Furthering Access to Coordinated Treatment for Seniors Act of 2017--provisions to provide prescription drug plans with Medicare Parts A and B data. Draft legislation "to amend title XVIII of the Social Security Act to provide for electronic prior authorization under Medicare Part D for covered part D drugs and for other purposes" (House only).

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2017

Q2 Report

In Q2, Prime Therapeutics had in-house lobbyists. The report was filed on July 18, 2017. Original Filing: 300887903.xml

Lobbying Issues

H.R.2430/S.934: FDA Reauthorization Act of 2017--provisions to ensure greater market competition for generics & biosimilars. S.469/H.R.1245: Affordable and Safe Prescription Drug Importation Act --issues relating to noninterference and workability. S.778: Prescription Drug Monitoring Act--issues related to dispensers access to PDMP data across state lines. S.771/H.R.1776: Improving Access to Affordable Prescription Drugs Act--issues related to ensuring a competitive marketplace for prescription drugs. H.R.1939/S.1044: Ensuring Seniors Access to Local Pharmacies Act of 2017 (any willing pharmacy bill)--Provisions limiting payers' ability to selectively contract. Use of prescription drug coupons in federal programs and the ACA exchanges and their effects on insurance premiums. S.1003: To amend title XIX of the Social Security Act to add standards for drug compendia for physician use for purposes of Medicaid payment for certain drugs, and for other purposes; provisions related do drug coverage in Medicare and Medicaid. H.R.1703: Medical Product Communications Act of 2017--provisions relating to greater market access for off-label indications.

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R.749: "Lower Drugs Costs Through Competition Act,"--increasing generic competition. Legislation to address abuses of the REMS program to allow generic drugs to come to market faster.H.R.2212/S.974: CREATES Act--provisions related to removing barriers to generic competition.H.R.2430/S.934: FDA Reauthorization Act of 2017--provisions to ensure greater market competition for generics & biosimilars. S.469/H.R. 1245: Affordable and Safe Prescription Drug Importation Act--issues relating to noninterference and workability. H.R.1939/S.1044: Ensuring Seniors Access to Local Pharmacies Act of 2017 (any willing pharmacy bill)--provisions limiting payers' ability to selectively contract. Use of prescription drug coupons in federal programs and the ACA exchanges and their effects on insurance premiums. H.R.1628: The American Health Care Act of 2017 and The Better Care Reconciliation Act--provisions related to the stability of the exchanges. H.R.1316: The Prescription Drug Price Transparency Act--issues related to ensuring the continuity of MAC pricing. S.771/H.R.1776: Improving Access to Affordable Prescription Drugs Act--issues related to ensuring a competitive marketplace for prescription drugs. H.R.1703: Medical Product Communications Act of 2017--provisions relating to greater market access for off-label indications. S.778 Prescription Drug Monitoring Act--issues related to dispensers access to PDMP data across state lines. H.R.2026: Pharmaceutical Information Exchange Act--provisions relating to payer access to pharma data. H.R.2051: The FAST Generics Act--provisions that expedite market access for generics.

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R.413/H.R.1038: Improving Transparency and Accuracy in Medicare Part D Spending Act--provisions restricting payer quality payment programs in Medicare Part D. Draft bill to amend title XVIII of the Social Security Act to provide for greater access to drug cost information for Medicare beneficiaries by preventing cash price disclosure restrictions under Medicare prescription drug plan contracts with pharmacies--issues related to Medicare non-interference. S.469/H.R.1245: Affordable and Safe Prescription Drug Importation Act--issues relating to noninterference and workability. S.771/H.R.1776: Improving Access to Affordable Prescription Drugs Act--issues related to ensuring a competitive marketplace for prescription drugs. H.R.1939/S.1044, Ensuring Seniors Access to Local Pharmacies Act of 2017 (any willing pharmacy bill)--provisions limiting payers' ability to selectively contract. Use of prescription drug coupons in federal programs and the ACA exchanges and their effects on insurance premiums. S. 1003: To amend title XIX of the Social Security Act to add standards for drug compendia for physician use for purposes of Medicaid payment for certain drugs, and for other purposes. Provisions related do drug coverage in Medicare and Medicaid. H.R.1316: The Prescription Drug Price Transparency Act -Issues related to ensuring the continuity of MAC pricing. S.637: Creating Transparency to Have Drug Rebates Unlocked (C-Thru) Act--issues relating to Medicare Part D cash price disclosure. H.R.1628: The American Health Care Act of 2017 and The Better Care Reconciliation Act--Provisions related to the stability of the exchanges. Draft bill to amend part A of title XVIII of the Social Security Act to provider greater access to information regarding the items and services furnished to the individual under parts A and B of the Medicare program and greater context regarding the medication regimen of the individual, issues relating to use of Medicare data.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2017

Q1 Report

In Q1, Prime Therapeutics had in-house lobbyists. The report was filed on April 19, 2017. Original Filing: 300870733.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

HR 749: Lower Drug Costs Through Competition Act - increasing generic competition. Legislation to address abuses of the REMS program to allow generic drugs to come to market faster. Generic drug user fee act - provisions to ensure greater market competition for generics. Biosimilar drug user fee act - ensuring greater competition in the biosimilar market. HR 1121: Preexisting Conditions Protect Act of 2017 - issues relating to market stability in exchanges. S. 191: Patient Freedom Act of 2017 - issues relating to market stability in exchanges. S. 469/H.R. 1245: Affordable and Safe Prescription Drug Importation Act. H.R. 1316: The Prescription Drug Price Transparency Act - issues relating to ensuring continued use of MAC pricing. S. 771/H.R. 1776: Improving Access to Affordable Prescription Drugs Act - issues relating to ensuring a competitive drug marketplace. H.R. 1628: The American Health Care Act of 2017 - issues related to market stabilization. S.778: Prescription Drug Monitoring Act - issues related to dispensers access to PDMPs across state lines.

Agencies Lobbied

Type of Issue

Lobbying Issues

S.413/H.R.1038: Improving Transparency and Accuracy in Medicare Part D Spending Act - restrictions on payor quallity programs in Medicare Part D. Draft bill to amend title XVIII of the Social Security Act to provide for greater access to drug cost information for Medicare beneficiaries by preventing cash price disclosure restrictions under Medicare prescription drug plan contracts with pharmacies - issues related to noninterference in Medicare Part D. Counter efforts to elimination of the Medicare Part D non-interference clause. H.R. 1316: The Prescription Drug Price Transparency Act - issues relating to ensuring continued use of MAC pricing. S. 637: Creating Transparency to Have Drug Rebates Unlocked (C-Thru) Act - Issues relating to Medicare Part D cash price disclosure. S.771/H.R.1776: Improving Access to Affordable Prescription Drugs Act - issues relating to ensuring a competitive drug marketplace. Draft bill to amend part A of title XVIII of the Social Security Act to provide greater access to information regarding the items and services furnished to the individual under parts A and B of the Medicare program and greater context regarding the medication regimen of the individual - issues relating to use of Medicare data.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2016

Q4 Report

In Q4, Prime Therapeutics had in-house lobbyists. The report was filed on Jan. 17, 2017. Original Filing: 300847693.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2016

Q3 Report

In Q3, Prime Therapeutics had in-house lobbyists. The report was filed on Oct. 19, 2016. Original Filing: 300832008.xml

Lobbying Issues

S.524: Comprehensive Addiction and Recovery Act, focused on Prescription Drug Management Plans (PDMPs), Medicare lock-in, partial fills and co-prescribing. S.480/H.R.1725: National All Schedules Prescription Electronic Reporting Reauthorization Act of 2015, educating on the importance of PDMPs and the need for federal funding. H.R.4981: The Opioid Use Disorder Treatment Expansion and Modernization Act. H.R.4599/S.2578: Reducing Unused Medications Act of 2016. H.R.3680: Co-Prescribing to Reduce Overdoses Act of 2016. S.2256: Co-Prescribing Saves Lives Act of 2016. H.R.4784: Lower Drug Costs Through Competition Act, support increasing generic availability. S.2680: A bill to amend the Public Health Service Act to provide comprehensive mental health reform, and for other purposes. S.2615: the Increasing Competition in Pharmaceuticals Act.

Agencies Lobbied

Type of Issue

Lobbying Issues

S.524: Comprehensive Addiction and Recovery Act, focused on Prescription Drug Management Plans (PDMPs), Medicare lock-ins, partial fills and co-prescribing. S.480/H.R.1725: National All Schedules Prescription Electronic Reporting Reauthorization Act of 2015, educating on the importance of PDMPs and the need for federal funding. HR.4981: The Opioid Use Disorder Treatment Expansion and Modernization Act. H.R.4599/S.2578: Reducing Unused Medications Act of 2016. H.R.3680: Co-Prescribing to Reduce Overdoses Act of 2016. S.2256: Co-Prescribing Saves Lives Act of 2016. S.1945: Senate HELP mental health reform package, Mental Health Reform Act of 2016, mental health parity treatment of step therapy and prior-authorization. S.2615: Increasing Competition in Pharmaceuticals Act, support increasing generic availability. H.R.6: The 21st Century Cures Act and Senate companions, ensuring no new barriers to generic and biosimilar market entry. Generic Drug User Fee Act Reauthorization, support increasing generic availability. H.R.1600: The Patients' Access to Treatment Act, educating on the importance of step therapy to ensuring optimal therapy access and cost control. H.R.2841: the FAST Generics Act. S.3056: the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act. S.2700: Workforce Authorities Modernization Act, Section 11, Biological Product Innovation - treatment of USP compendia in approving biologics and biosimilars. Role of PBMs in Mylan pricing before Congressional hearings/investigation of Mylan. Drug pricing in general. H.R.6043 and S.3335, "Fair Accountability and Innovative Research Drug Pricing Act of 2016".

Agencies Lobbied

Type of Issue

Lobbying Issues

Potential future guidance on DIR: Direct and Indirect Renumeration for Pharmacies. S.524: "Comprehensive Addiction and Recovery Act," focused on Prescription Drug Management Plans (PDMPs). S.480/H.R.1725: "National All Schedules Prescription Electronic Reporting Reauthorization Act of 2015," educating on the importance of PDMPs and the need for federal funding. H.R.4981: The Opioid Use Disorder Treatment Expansion and Modernization Act. H.R.4599/S.2578: Reducing Unused Medications Act of 2016. H.R.3680: Co-Prescribing to Reduce Overdoses Act of 2016. S.2256: Co-Prescribing Saves Lives Act of 2016. H.R.244: "MAC Transparency Act," educating on how MAC pricing helps control costs for consumers. H.R.793/S.1190: "Ensuring Seniors Access to Local Pharmacies Act of 2015," importance of pharmacy networks in reducing costs. H.R.1600: "The Patients' Access to Treatment Act," educating on the importance of step therapy to ensuring optimal therapy access and cost control. Drug pricing in general. H.R.5951 and S.3308, Improving Transparency and Accuracy in Medicare Part D Spending Act.

Agencies Lobbied

Type of Issue

2nd Quarter, 2016

Q2 Report

In Q2, Prime Therapeutics had in-house lobbyists. The report was filed on July 19, 2016. Original Filing: 300813114.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2016

Q1 Report

In Q1, Prime Therapeutics had in-house lobbyists. The report was filed on April 19, 2016. Original Filing: 300796360.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

S.524, "Comprehensive Addiction and Recovery Act," focused on Prescription Drug Management Plans (PDMPs). S.1945, Senate HELP mental health reform package, "Mental Health Reform Act of 2016," mental health parity treatment of step therapy and prior-authorization. S.2615, "Increasing Competition in Pharmaceuticals Act," support increasing generic availability. H.R.6, "The 21st Century Cures Act" and Senate companions, ensuring no new barriers to generic and biosimilar market entry. Generic Drug User Fee Act Reauthorization, support increasing generic availability. H.R.1600, "The Patients' Access to Treatment Act," educating on the importance of step therapy to ensuring optimal therapy access and cost control. S.480/H.R.1725, "National All Schedules Prescription Electronic Reporting Reauthorization Act of 2015," educating on the importance of PDMPs and the need for federal funding.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2015

Q4 Report

4th Quarter, 2015

Termination

3rd Quarter, 2015

Q3 Report

In Q3, Prime Therapeutics had in-house lobbyists. The report was filed on Oct. 20, 2015. Original Filing: 300763070.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2015

Q2 Report

In Q2, Prime Therapeutics had in-house lobbyists. The report was filed on July 20, 2015. Original Filing: 300740670.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R. 793: Ensuring Seniors Access to Local Pharmacies Act of 2015. Importance of pharmacy networks in reducing costs. H.R. 244: MAC Transparency Act. Educating on how MAC pricing helps control costs for consumers. Prescription Drug Abuse - Patient Review and Restriction programs for the Medicare program H.R. 793: Ensuring Seniors Access to Local Pharmacies Act of 2015. Importance of pharmacy networks in reducing costs. H.R. 244: MAC Transparency Act. Educating on how MAC pricing helps control costs for consumers. Prescription Drug Abuse - Patient Review and Restriction programs for the Medicare program S.480 - National All Schedules Prescription Electronic Reporting Reauthorization Act of 2015 CY 2016 Notice of Benefit and Payment Parameters (CMS-9944-P)

Agencies Lobbied

Type of Issue

1st Quarter, 2015

Q1 Report

In Q1, Prime Therapeutics had in-house lobbyists. The report was filed on April 21, 2015. Original Filing: 300728051.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2014

Q4 Report

In Q4, Prime Therapeutics had in-house lobbyists. The report was filed on Jan. 19, 2015. Original Filing: 300700334.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2014

Q3 Report

In Q3, Prime Therapeutics had in-house lobbyists. The report was filed on Oct. 20, 2014. Original Filing: 300688699.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2014

Q2 Report

In Q2, Prime Therapeutics had in-house lobbyists. The report was filed on July 21, 2014. Original Filing: 300668926.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2014

Q1 Report

In Q1, Prime Therapeutics had in-house lobbyists. The report was filed on April 21, 2014. Original Filing: 300646554.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2013

Q4 Report

In Q4, Prime Therapeutics had in-house lobbyists. The report was filed on May 8, 2014. Original Filing: 300651411.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2013

Q3 Report

In Q3, Prime Therapeutics had in-house lobbyists. The report was filed on Oct. 25, 2013. Original Filing: 300608560.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2013

Q2 Report

In Q2, Prime Therapeutics had in-house lobbyists. The report was filed on July 22, 2013. Original Filing: 300581471.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2013

Q1 Report

In Q1, Prime Therapeutics had in-house lobbyists. The report was filed on April 24, 2013. Original Filing: 300565450.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2012

Q4 Report

In Q4, Prime Therapeutics had in-house lobbyists. The report was filed on Jan. 18, 2013. Original Filing: 300533687.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2012

Q3 Report

In Q3, Prime Therapeutics had in-house lobbyists. The report was filed on July 24, 2012. Original Filing: 300500215.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2012

Q2 Report

In Q2, Prime Therapeutics had in-house lobbyists. The report was filed on Sept. 20, 2012. Original Filing: 300502899.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2012

Q1 Report

In Q1, Prime Therapeutics had in-house lobbyists. The report was filed on April 24, 2012. Original Filing: 300476475.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2011

Q4 Report

In Q4, Prime Therapeutics had in-house lobbyists. The report was filed on Jan. 20, 2012. Original Filing: 300452356.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2011

Q3 Report

In Q3, Prime Therapeutics had in-house lobbyists. The report was filed on Oct. 14, 2011. Original Filing: 300414461.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2011

Q2 Report

In Q2, Prime Therapeutics had in-house lobbyists. The report was filed on July 20, 2011. Original Filing: 300403400.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2011

Q1 Report

In Q1, Prime Therapeutics had in-house lobbyists. The report was filed on April 20, 2011. Original Filing: 300373754.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2010

Q4 Report

In Q4, Prime Therapeutics had in-house lobbyists. The report was filed on Jan. 20, 2011. Original Filing: 300351863.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2010

Q3 Report

In Q3, Prime Therapeutics had in-house lobbyists. The report was filed on Oct. 20, 2010. Original Filing: 300327958.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2010

Q2 Report

In Q2, Prime Therapeutics had in-house lobbyists. The report was filed on July 20, 2010. Original Filing: 300299149.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2010

Registration

1st Quarter, 2010

Q1 Report

4th Quarter, 2009

Q4 Report

In Q4, Prime Therapeutics had in-house lobbyists. The report was filed on Jan. 18, 2010. Original Filing: 300234371.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2009

Q3 Report

In Q3, Prime Therapeutics had in-house lobbyists. The report was filed on Oct. 26, 2009. Original Filing: 300223438.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2009

Q2 Report

In Q2, Prime Therapeutics had in-house lobbyists. The report was filed on July 9, 2009. Original Filing: 300174105.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2009

Q1 Report

In Q1, Prime Therapeutics had in-house lobbyists. The report was filed on April 20, 2009. Original Filing: 300163463.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2008

Q4 Report

In Q4, Prime Therapeutics had in-house lobbyists. The report was filed on Jan. 7, 2009. Original Filing: 300114244.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2008

Q3 Report

In Q3, Prime Therapeutics had in-house lobbyists. The report was filed on Oct. 15, 2008. Original Filing: 300092659.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2008

Registration

Source: Clerk of the U.S. House of Representatives and Secretary of the Senate

Legislators

Bills

Statements

Lobbying

Travel

Lobbyists

Disclosures Filed